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I 
PREFACE 
Increasing evidence proves that epigenetic mechanisms are importantly involved in 
the pathophysiology of psychiatric disorders. This is primarily based on findings of 
epigenetic regulation in post mortem brains and the working mechanisms of 
currently used pharmaceuticals. Epigenetic dysregulation caused by genetic variants 
and environmental exposures are potentially reversible. However, our knowledge on 
epigenetic regulation in the brain is still limited. 
 
This dissertation: ”The influence of DNA methylation on gene expression involved 
in the etiology and treatment of psychiatric disorders” has been submitted to the 
Faculty of Medicine, Aalborg University, Denmark. The dissertation presents 
experiments that investigate the influence of genetic variants on DNA methylation, 
correlations between DNA methylation and gene transcription in brain biopsies, 
activity-induced methylation changes in neurons, and pharmacological interventions 
targeting epigenetic mechanisms. 
 
The majority of experiments presented in this dissertation were conducted at the 
Laboratory of Neurobiology, Aalborg University, under the supervision of Associate 
Professor Jacek Lichota. The experiments involving BRD1 were conducted at 
Professor Anders Børglums laboratory, Department of Human Genetics, Aarhus 
University, under supervision of Associate Professor Jane H. Christensen.  
 
During my PhD study I have supervised students at the educations MedIS and 
Medicine, and participated in PhD courses corresponding to 30.65 ECTS points. 
Together these activities correspond to nearly a full year of my PhD study. 
 
The dissertation is based on five manuscripts of which two have been published and 
the remaining three are in preparation. The thesis is composed of a general 
introduction encompassing the primary topics being explored in the manuscripts, 
objectives, manuscripts, and a general discussion. 
II 
ENGLISH SUMMARY 
Psychiatric disorders such as schizophrenia and depression have high life time 
prevalences and large costs for individuals as well as society. Common for both 
diseases is that the current medications target the same basic mechanisms as those 
discovered by serendipity several decades ago. The primary reason is that our 
knowledge on pathophysiology of psychiatric disorders is still sparse.  
 
Family studies have revealed high heritability for schizophrenia and moderate 
heritability for depression. These observations have been succeeded by genetic 
studies that have revealed a high number of genetic variants associated with both 
diseases. In addition, a number of environmental risk factors have been identified. 
Both genetic variations and environmental exposures are known to influence 
epigenetic modifications. Adverse epigenetic modifications can potentially cause 
long-term dysregulation of genes and be implicated in pathophysiology. 
Importantly, these mechanisms can be modulated by pharmaceuticals and hence 
offer an alternative strategy for treating and preventing psychiatric disorders.  
 
The first part of this PhD dissertation focus on a single nucleotide polymorphism, 
rs138880, which is located in the BRD1 promoter region and has repeatedly been 
linked with schizophrenia. BRD1 is a transcription factor essential during 
embryogenesis and CNS development and is widely expressed in the adult brain. It 
is first established that DNA methylation plays a central role in regulating BRD1 
transcription. We then determine that the schizophrenia-risk allele of rs138880 is 
associated with increased DNA methylation. Importantly, we demonstrate that the 
affected regions undergo dynamic changes in DNA methylation levels during fetal 
brain development. This suggests that BRD1 may be dysregulated in carriers of the 
rs138880 risk allele in both the developing and mature brain. 
 
In the second part, we focus on the CHRNA7 gene, encoding the α7 nicotinic 
acetylcholine receptor, which is considered a promising target for treatment of 
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cognitive dysfunction in schizophrenia. DNA methylation of the CHRNA7 core 
promoter has previously been implicated in transcriptional regulation and we 
identify two other important regions. Clinical trials with the α7 nicotinic 
acetylcholine receptor have been challenged by relatively modest effect sizes and 
large inter-individual response variations. These variations have been suggested to 
result from genetic variations and we use human brain biopsies to investigate if 
DNA methylation could be involved. Finally, we use cell lines to demonstrate the 
potential of pharmacologically modulating receptor expression.  
 
In the final part, we concentrate on electroconvulsive therapy (ECT), one of the 
most effective treatments of major depression. Electroconvulsive stimulation (ECS), 
an animal model of ECT, has been extensively studied in attempts to identify novel 
treatment mechanisms. Unfortunately, ECT is also characterised by side effects 
including memory deficits, which are reported by some patients. In three 
consecutive studies we study both positive and adverse expression changes caused 
by ECS. Recent studies have identified neuronal activity-dependent methylation 
changes and in this relation we focus specifically on the gene Arc, which plays an 
important role in long-term synapse-specific modifications important for memory 
processes.  
 
Findings of this research emphasise the importance and potential of studying 
epigenetic mechanisms in psychiatric disorders. They indicate how a genetically 
associated risk variant can lead to dysregulation, how DNA methylation is involved 
in transcriptional regulation in the brain, and how neuronal activity leads to active 
methylation and demethylation that can be involved in both beneficial and adverse 
processes. 
 
 
 
 
 
IV 
DANSK RESUME 
Psykiske sygdomme såsom skizofreni og depression har høje livstidsprævalenser og 
store omkostninger for både individet og samfundet. Fælles for begge sygdomme er, 
at de nuværende behandlinger er rettet mod de samme mekanismer, som tilfældigt 
blev opdaget for adskillige årtier siden. Den primære årsag, til at behandlingen ikke 
har udviklet sig, er, at vores viden om patofysiologien af psykiatriske lidelser til 
stadighed er begrænset.  
 
Familiestudier har for årtier siden afsløret, at arveligheden for skizofreni er høj og 
moderat for depression. Efterfølgende har genetiske studier afsløret en lang række 
genetiske risikovarianter for begge sygdomme. Derudover er en række 
miljømæssige risikofaktorer blevet identificeret. Både genetiske variationer og 
miljøet kan påvirke epigenetiske modifikationer. Skadelige epigenetiske 
modifikationer kan potentielt forårsage langvarig dysregulering af genekspression 
og være involveret i sygdommenes patofysiologi. Disse epigenetiske modifikationer 
kan dog moduleres med lægemidler og kan derfor potentielt bruges som en 
alternativ strategi til at behandle og forhindre psykiatriske lidelser.  
 
Den første del af denne afhandling fokuserer på en enkeltnukleotidpolymorfi, 
rs138880, der er lokaliseret i promoterregionen af BRD1 genet, og som gentagne 
gange er blevet associeret med skizofreni. BRD1 er en transskriptionsfaktor, der er 
essentiel for embryogenesen samt centralnervesystemets udvikling og den er højt 
udtrykt i den voksne hjerne. Først påvises det, at DNA metylering spiller en central 
rolle i reguleringen af BRD1 transskriptionen. Dernæst afslører vi, at skizofreni-
risiko-allelen af rs138880 er associeret med øget DNA metylering i bestemte 
regioner. Endvidere påviser vi, at de ramte regioner normalt gennemgår dynamiske 
ændringer i metyleringsgrad i løbet af fosterets hjerneudvikling. Dette indikerer, at 
BRD1 kan være dysreguleret i både fosterstadiet og den voksne hjerne hos bærere af 
rs138880 risiko-allelen.  
V 
I den anden del fokuserer vi på α7 nikotinreceptoren, der betragtes som en lovende 
kandidat for behandling af kognitiv dysfunktion hos skizofrene. Det er tidligere 
blevet vist, at DNA metylering omkring transkriptionsstartstedet for α7 
nikotinreceptor-genet er vigtig for transkriptionel regulering, og vi identificerer 
yderligere to vigtige områder. Klinisk afprøvning af α7 nikotinreceptor-agonister er 
blevet vanskeliggjort af begrænsede effektstørrelser og store inter-individuelle 
responsvariationer. Det er tidligere blevet foreslået, at disse variationer skyldes 
genetiske varianter, og vi bruger humane hjernebiopsier til at undersøge, om DNA 
metylering også kan spille en rolle. Endvidere bruger vi cellelinjer til at 
demonstrere, at α7 nikotinreceptor-ekspressionen potentielt kan moduleres ved 
farmakologisk intervention.  
 
I den sidste del fokuserer vi på elektrokonvulsiv terapi (ECT), som er en af de mest 
effektive behandlinger af depression. Elektrokonvulsiv stimulation (ECS), en 
dyremodel for ECT, er hyppigt blevet brugt i forsøg på at identificere nye potentielle 
behandlingsmekanismer. ECT er imidlertid også karakteriseret af bivirkninger, 
herunder hukommelsesproblemer, som rapporteres af nogle patienter. I tre 
fortløbende studier undersøger vi både virknings- og bivirkningsrelaterede 
ekspressionsændringer forårsaget af ECS. Nyere studier har afsløret, at neuronal 
aktivitet resulterer i metyleringsændringer, og i den sammenhæng fokuserer vi på 
Arc genet, som spiller en vigtig rolle i langvarige synapse-specifikke modifikationer, 
der er vigtige for hukommelsesprocesser.  
 
Resultaterne af denne forskning understreger vigtigheden og potentialet af at studere 
epigenetiske modifikationer i relation til psykiatriske sygdomme. Ydermere 
indikerer de, hvordan en genetisk risikovariant kan føre til dysregulering af 
genekspressionen, hvilken rolle DNA metylering spiller i regulering af 
genekspression i hjernen, og hvordan neuronal aktivitet kan føre til aktiv metylering 
og demetylering, som både kan være gavnlig og uønsket.  
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1. INTRODUCTION 
This PhD dissertation is centered around five manuscripts that collectively focus on 
DNA methylation alterations involved in the etiology and treatment of psychiatric 
disorders. While the studied mechanisms are conjoint, the diseases are distinctive 
although having common features. The primary focus of the five included papers 
are: 1) a single nucleotide polymorphism (SNP) that has been linked to 
schizophrenia 2) regulation of the α7 nicotinic acetylcholine receptor (nAChR), 
which is a promising target for treating cognitive dysfunction in schizophrenic 
patients 3) effects and side-effects resulting from electroconvulsive therapy (ECT), a 
treatment commonly used for major depression. The purpose of this chapter is to 
introduce the topics most relevant for this dissertation. Epigenetic mechanisms and 
schizophrenia will be thoroughly introduced whereas the presentation of depression 
is more restricted and focus primarily on molecular mechanisms relevant for ECT.  
1.1. EPIGENETIC MECHANISMS 
Gene function may be altered by either a change in DNA sequence or changes in 
epigenetic programming of the gene. The following sections will start by 
introducing DNA methylation and histone modification and although described in 
separate sections these mechanisms are highly interconnected. The traditional 
definition of epigenetic mechanisms requires that the mechanisms must be heritable 
either across the germ line or cell divisions (Bird 2007). As neurons cannot divide 
and are not germ cells, the mechanisms occurring in the adult central nervous system 
(CNS) do not qualify as being epigenetic by this definition (Day & Sweatt 2010). 
However, several studies have demonstrated that modification of chromatin 
structure and DNA methylation are critical for functions in the CNS. These 
processes can be described as neuroepigenetic to distinguish them from traditional 
heritable epigenetic marks involved in development and cell differentiation (Day & 
Sweatt 2010). A separate section will describe neuroepigenetics. Finally, the basic 
principles of drugs targeting epigenetic mechanisms relevant for psychiatric 
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disorders will be described as these have the potential to alter gene expression 
profiles. 
1.1.1. DNA METHYLATION 
In 1975 it was suggested for the first time that methylation of cytosine residues in a 
CpG dinucleotide context could serve as an epigenetic mechanism in vertebrates 
(Holliday & Pugh 1975; Riggs 1975). It was proposed that CpG sites could be 
methylated de novo, that enzymes recognising hemimethylated DNA can allow 
inheritance through somatic cell division, that methyl groups can be interpreted by 
DNA-binding proteins, and that DNA methylation silences genes. Although these 
assumptions have turned out correct, the relationship between DNA methylation, 
gene silencing, and responsible mechanisms has been difficult to unravel (Jones 
2012). The highly stable covalent modification of DNA produces potentially life 
long changes in gene expression making it essential for maintaining stable cellular 
identities (Gavin et al. 2013). So far most studies have been focused on 5-
methylcytosine in a CpG context and have particularly focused on CpG islands 
located in promoter regions of approximately 60% of genes in the vertebrate genome 
(Wang & Leung 2004). More recently, the focus has expanded to include low 
density CpG promoters and methylation at gene bodies, enhancers, and insulators 
(Jones 2012). 
1.1.1.1. Enzymes catalyse methylation and demethylation 
The function of DNA methylation is inevitably linked to the mechanisms 
responsible for establishing, maintaining, and removing the methyl group. The 
functions of DNA methyltransferases: DNMT1, DNMT3a, and DNMT3b have been 
extensively studied and it has long been known that de novo methyltransferases 
DNMT3a and DNMT3b are essential for setting up DNA methylation patterns in 
early development (Jones & Liang 2009). It was originally thought that DNMT1 
could maintain an established methylation pattern, but later it was discovered that 
DNMT3a and DNMT3b are also actively involved (Jones & Liang 2009). However, 
the mechanisms that guide a DNMT to a specific CpG have not been fully 
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elucidated, but most likely it occurs through interactions with transcription factors 
and chromatin proteins (Gavin et al. 2013).  
   The existence of active DNA demethylation mechanisms was controversial for 
many years (Ooi & Bestor 2008). However, now both direct and indirect evidence 
points for their existence. The abundant expression of DNMTs in neurons implies a 
DNA demethylation pathway (Sharma et al. 2008), because otherwise aging should 
gradually result in accumulating DNA methylation and this is not the case (Numata 
et al. 2012). It has also been demonstrated that activity dependent demethylation 
occurs in neurons (Miller & Sweatt 2007; Levenson et al. 2006; Feng et al. 2010a). 
Further, many DNMT inhibitors are cytosine analogs and functions by incorporating 
into DNA where they trap DNMTs and this mechanism also occurs in non-dividing 
cells (Yamagata et al. 2012). The most consistent observation is that DNA 
demethylation may occur by a base excision repair process. This process initially 
involves oxidisation of 5-methylcytosine (5mc) to form 5-hydroxymethylcytosine 
(5hmc) in a process catalysed by ten-eleven translocation (TET) enzymes (Guo et al. 
2011a; Ito et al. 2010; Koh et al. 2011). 5hmc may further be oxidised by TET 
enzymes to form 5-formylcytosine (5fc) and subsequently 5-carboxylcytosine (5cac) 
(Ito et al. 2011). Alternatively 5mc or 5hmc can be deaminated by activation-
induced cytidine deaminase (AICDA) or apolipoprotein B mRNA editing enzyme, 
catalytic polypeptide-like (APOBEC) forming either thymidine or 5-
hydroxymethyluracil (5hmu). Overall this may result in mismatches 5cac:G, T:G, or 
5hmu:G that are removed through a process involving thymidine or uracil 
glycosylases (Guo et al. 2011a). In this demethylation process it is suspected that 
Gadd45 proteins bind to and direct the enzymatic activities to specific gene 
promoters (Cortellino et al. 2011; Rai et al. 2008).  
 
1.1.1.2. Characteristics of CGI and non-CGI promoters 
The CpG site density varies considerably in mammalian promoters and although the 
density follows a bimodal distribution, some promoters have intermediate CpG 
density (Takai & Jones 2002). In somatic cells most CGI-promoters are 
unmethylated. The active CGI-promoters are characterised by nucleosome-depleted 
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regions that are flanked by the histone variant H2A.Z and marked with the histone 
modification H3K4me3 (Kelly et al. 2010) (Figure 1). H2A.Z and H3K4me3 are 
anti-correlated with DNA methylation (Zilberman et al. 2008; Conerly et al. 2010). 
The activating histone marks H3K4me2 and H3K4me3 that are usually found near 
TSSs of active genes have also been found to block de novo methylation (Ooi et al. 
2007). In addition, it has been found that DNMT binding requires nucleosomes as a 
substrate (Ooi et al. 2007). 
   For the subset of promoters that do become highly methylated at a CGI, this 
usually occurs when there is long-term stabilisation of the repressed state such as 
during imprinting. The mechanism by which DNA methylation represses 
transcription of a CGI-promoter has been well described. The promoter has 
nucleosomes at the TSS that are marked with repressive H3K9me3 (Lin et al. 2007) 
and bound by methylated DNA binding proteins that recruit histone deacetylases 
(HDACs) (Wade & Wolffe 2001). Methylated DNA is recognised by methyl 
binding domain proteins (MBDs), such as MeCP2 that are part of large protein 
complexes containing HDACs and histone methyltransferases (HMTs) resulting in 
further transcriptional repression (Tsankova et al. 2007). Consequently the DNA is 
assembled to nucleosomes and this prevents initiation of transcription at the TSS 
(Venolia & Gartler 1983; Hashimshony et al. 2003; Kass et al. 1997). 
   In contrast to the stability of methylation at CGI-promoters of silent genes, 
substantial fluctuations occur at non-CGI promoters. While the consequences of 
methylation of non-CGI promoters have been less well-studied evidence suggests 
that it is also important for repressing transcription. Indeed genome-wide analysis 
has revealed that there is an inverse relationship between methylation of non-CGI 
promoters and expression (Gal-Yam et al. 2008). However, because research up to 
this point has been highly focused on CGIs, little is known about the specific 
functions. However, it seems most likely that DNA methylation and repressive 
histone modifications work in concert to cause chromatin condensation and 
transcriptional repression.  
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Figure 1. Molecular structure of chromatin illustrating the role of CpG methylation in 
regulating gene expression. More than half of human genes have CpG islands (CGIs) at their 
promoters. Active genes are characterised by nucleosome-depleted regions (NDR) at the 
transcriptional start site (TSS). DNMTs need nucleosomes to bind and the nucleosomes 
flanking the TSS are marked with H3K4me3 and the histone variant H2A.Z which prevents 
DNMT binding. The gene body is mostly CpG depleted and the CpG sites are mostly 
methylated. Gene body methylation patterns have revealed that exons are more highly 
methylated than introns and that this shift occurs at the exon-intron boundary, suggesting a 
possible role in splicing. DNA methylation is maintained by DNMT1 and DNM3A and/or 
DNMT3B. Enhancers are usually CpG poor and show variable methylation, which suggests 
that levels may be dynamically regulated. When active, these regions are also nucleosome-
depleted and flanking nucleosomes are marked with H3K4me1 and H2A.Z. Proteins such as 
CTCF are known to bind to insulators. When these are unmethylated the region is 
nucleosome-depleted, whereas increased methylation changes this and is known (in some 
cases) to block binding of CTCF. CpG-poor promoters and silenced CGIs are not illustrated 
but are both in the silent state associated with nucleosomes at the TSS. LMR: Low-
methylated region (LMR). Modified from (Jones 2012). 
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1.1.1.3. Changes in transcriptional activity lead to methylation or 
demethylation 
As described above, methylation of a CGI causes the region to assemble to 
nucleosomes and this prevents initiation of transcription at the TSS (Venolia & 
Gartler 1983; Hashimshony et al. 2003; Kass et al. 1997). However, it still remains 
controversial whether silencing or methylation comes first.  
   Experiments have shown that methylation of HPRT occurred as a secondary event 
after inactivation of one X chromosome (Lock et al. 1987) and in cancer cells there 
is strong evidence that CGI promoters that are silenced by Polycomb complexes are 
much more likely to become methylated (Gal-Yam et al. 2008; Ohm et al. 2007; 
Schlesinger et al. 2007; Widschwendter et al. 2007). In addition, DNA mutations 
that affect promoter activity have shown to affect DNA methylation. By studying 
promoter SNPs that alter transcriptional drive, it has been found that a CpG island in 
a less active allele was more likely to become de novo methylated (Hitchins et al. 
2011) whereas the opposite was observed for an allele that had an additional binding 
site for an activating transcription factor (Boumber et al. 2008).    
   While not all promoters are de novo methylated, the observation above predicts 
that a promoter is more likely to become methylated when gene transcription 
decreases. However, these observations suggest that DNA methylation is probably 
not an initial silencing method and this notion is supported by studies on de novo 
methyltransferases. By doing experiments with cells expressing DNMT3L (a 
catalytically inactive homologue of DNMT3a and DNMT3b) it was found that de 
novo methylation was achieved by a tetrameric complex of two molecules each of 
DNMT3A2 and DNMT3L and that a nucleosome was required for binding of the 
complex (Ooi et al. 2007). This sequence of events has also been observed for 
specific genes during cellular differentiation. Here transcription factor binding is 
lost, which results in occurrence of a nucleosome, followed by DNMT3A binding, 
and subsequently de novo methylation (You et al. 2011) (Figure 2). 
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Figure 2. A decrease in promoter 
activity occurs before DNA 
methylation. Active promoters and 
enhancers are characterised by 
nucleosome-depleted regions where 
transcription factors (in this case 
OCT4 and SOX2) and chromatin 
remodellers bind. NANOG may bind 
in the proximal promoter (not 
illustrated). Loss of transcription 
factor binding as occurs during 
embryonic carcinoma cell 
differentiation where OCT4 and 
NANOG are downregulated, or in 
situations where SNPs disrupt a 
transcription factor binding site, 
nucleosome occupancy at the region 
increases. This provides a substrate 
for de novo methyltransferases and 
silencing of the gene. Modified from 
(Jones 2012).  
 
  
 
For non-CGI promoters the causality of methylation changes has still not been fully 
resolved. It is known that some transcription factors can bind strongly to methylated 
DNA which leads to passive regional demethylation (Hsieh 2000) and hence it is not 
known if methylation is merely present to stabilise transcriptionally incompetent 
states. However, there are large variations in how methylation affects transcription 
factor binding. For example it is known that SP1 is unaffected by methylation 
(Harrington et al. 1988) whereas binding of MYC is directly inhibited (Prendergast 
& Ziff 1991). Epigenome-wide scans show that transcription factor binding is 
strongly influenced by methylation within their recognition sites (Chen et al. 2011). 
In some cases methylation within 100 bp in each side of the target sequence is 
sufficient for hindering binding (You et al. 2011). In general the strength of 
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repression correlates with the extent of DNA methylation and while heavily 
methylated genes are irreversibly silenced, strong activators may overcome lower 
degrees of methylation (Williams et al. 2011; Bell & Felsenfeld 2000).  
 
1.1.1.4. Gene body methylation correlates with transcriptional 
activation 
Gene bodies are most frequently CpG poor with occasional CGIs and are 
extensively methylated (Jones 1999). It has long been known that active gene 
transcription is associated with gene body methylation (Wolf et al. 1984) and these 
observations have more recently been confirmed (Hellman & Chess 2007; Feng et 
al. 2010b). When CGIs are located in gene bodies they mostly remain unmethylated, 
however this is different in the human brain where 34% intragenic CGIs are 
methylated (Jones 2012). In cases with high intragenic CGI methylation this does 
not block transcription elongation, despite that these regions are marked with 
H3K9me3 and bound by MECP2 that represses transcription when present at the 
TSS (Nguyen et al. 2001). Therefore, only initiation of transcription is sensitive to 
methylation whereas elongation is not. Gene body methylation outside CGIs may be 
important for silencing repetitive DNA elements including retroviruses (Yoder et al. 
1997). Studies on gene body methylation patterns have revealed that exons are more 
highly methylated than introns and that this shift occurs at the exon-intron boundary, 
suggesting a possible role in splicing (Laurent et al. 2010). Indeed, methylation is 
known to prevent binding of CTCF, which has been found to result in pausing of 
RNA polymerase II, thereby potentially influencing splicing (Shukla et al. 2011). 
1.1.2. HISTONE MODIFICATIONS 
As described in the previous section, chromatin exists in many activity-states. The 
basic building block of chromatin is the nucleosome formed by an octamer of 
histone proteins and 147 bp DNA wrapped around the histone core. The general 
variants of histone proteins are linker histone H1 and H2A, H2B, H3, and H4. The 
nucleosome is composed of a H3-H4 tetramer flanked on both sides by a H2A-H2B 
dimer (Finch et al. 1977). Amino acid residues on amino (N)-terminal tails of 
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histones can be extensively modified by more than 100 covalent modifications 
including acetylation (Wade et al. 1997), methylation (Jenuwein 2001), sumoylation 
(Shiio & Eisenman 2003), phosphorylation (Oki et al. 2007) and ubiquitination 
(Shilatifard 2006). Enzymes that work bidirectionally adds or removes these marks 
and can be modulated by pharmaceuticals (Szyf 2009). The patterns of 
modifications are importantly involved in defining accessibility of the DNA to the 
transcription machinery. Histone acetylation is a mark of gene activity and 
chromatin decondensation, whereas methylation and phosphorylation can correlate 
with both transcriptional activation and repression, depending on the modified 
residues (Tsankova et al. 2007). With the diversity of modifications and their 
simultaneous influences, chromatin exists in a continuum of many structural states 
ranging from active euchromatin to condensed heterochromatin (Figure 3). Enzymes 
capable of catalysing and reversing most types of histone modifications have been 
identified. These are part of large multi protein complexes that control chromatin 
organisation and activity (Kouzarides 2007). Most histone acetyltransferases 
(HATs) can catalyse acetylation of several lysine residues whereas some have higher 
specificity and target specific residues (Lee & Workman 2007). By being part of 
large multi protein complexes it is believed that specific locations in the genome 
become targeted (Lee & Workman 2007).  
   It is believed that histone modifications control chromatin compaction by two 
primary mechanisms: Either by recruiting effector proteins or by directly altering 
chromatin structure. It has been found that acetylation of H4K16 neutralises the 
positive charge of the lysine and destabilises internucleosomal contacts of the 30 nm 
fiber which leads to decondensation (Shogren-Knaak et al. 2006). This can allow 
access of DNA binding proteins including transcription factors. The indirect 
mechanism of histone modifications is to recruit specific protein complexes to 
modification sites. Histone acetylation is recognised by bromodomains whereas 
chromodomains recognise histone methylation and these domains are part of larger 
protein complexes that further modify chromatin (Yang 2004; Choi & Howe 2009). 
In addition, the histone modifications may also sterically inhibit binding of proteins 
to chromatin (Kouzarides 2007). 
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Figure 3. Modifications responsible for the structural states of chromatin and enzymes 
involved in remodelling. DNA is wrapped around a histone octamer composed of two copies 
each of the histones H2A, H2B, H3, and H4 with modifiable amino (N) termini of the 
histones facing outward from the nucleosome complex. a) Chromatin exists in a continuum of 
many structural states ranging from active euchromatin to condensed heterochromatin. 
Acetylation (A), methylation (M), and phosphorylation (P) of histone tails and corresponding 
binding of transcription factors and co-activators (co-Act) or repressors (Rep) modulate 
structural states of the nucleosome. Active chromatin (top left) is characterised by histone 
acetylation that opens the nucleosome and allow binding of transcription factors and the basal 
transcriptional complex. The chromatin also occurs in permissive states (top right) and 
repressed states (bottom right). The inactivated condensed state (bottom left) occurs when 
gene activity is permanently silenced. b) Common covalent modifications of H3, including 
acetylation, methylation, and phosphorylation of amino acid residues. Acetylation and 
phosphorylation are activating whereas methylation can be either activating or repressing 
depending on the modified amino acid residue. Modifications are catalysed by groups of 
enzymes: Acetylation is catalysed by histone acetyltransferases (HATs) and reversed by 
histone deacetylases (HDACs); lysine methylation is catalysed by histone methyltransferases 
(HMTs) and reversed by histone demethylase (HDMs); phosphorylation is catalysed by 
protein kinases (PK) and may potentially be reversed by protein phosphatases (PP).  Modified 
from (Tsankova et al. 2007). 
 
   As described above DNA methylation binding proteins may recruit repressor 
complexes with histone deacetylase (HDAC) and histone methyltransferase (HMT) 
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activity. In addition, HDAC inhibition reduces global DNA methylation, DNMT1 
protein levels, and its interaction with chromatin (Arzenani et al. 2011), which 
further emphasises that these mechanisms are highly interconnected.  
 
1.1.3. NEUROEPIGENETICS: EPIGENETICS ARE IMPORTANT FOR 
NEURAL PLASTICITY 
The action of DNMTs is generally restricted to dividing cells and their mRNA 
expression is very high during development. However, in the adult brain which 
consists primarily of postmitotic neurons and glial cells the expression of DNMT1 
and DNMT3a mRNA is surprisingly high (Feng et al. 2010a). In the brain, 
neurotransmitters constitute the signalling mechanisms by which neurons 
communicate and the resulting synaptic changes may be importantly regulated by 
DNA methylation and histone modifications (Sharma & Chase 2012). Current 
evidence shows that DNA methylation is dynamically and bi-directionally regulated 
in the adult CNS (Miller & Sweatt 2007; Levenson et al. 2006; Feng et al. 2010a). 
Particularly, inhibition of DNMTs in the mammalian brain results in rapid and 
dramatic changes in DNA methylation of genes involved in synaptic plasticity 
(Levenson et al. 2006).  
   For several years it has been known that epigenetic mechanisms play a key role in 
memory formation in the adult brain (Day & Sweatt 2010). The first studies focused 
on the hippocampus, a region important for establishment of long-term spatial and 
episodic memory, and found that behavioural learning triggered changes in DNA 
methylation (Lubin et al. 2008; Miller & Sweatt 2007). Contextual fear conditioning 
results in transcriptional regulation of BDNF and changes in promoter DNA 
methylation status (Lubin et al. 2008). NMDA receptor blockade prevents both 
memory associated DNA methylation changes, transcriptional changes, and memory 
formation (Lubin et al. 2008). Memory formation involves both increased and 
decreased methylation as fear conditioning results in rapid methylation and 
transcriptional repression of the memory-suppressor gene Pp1 and demethylation 
and transcriptional activation of the plasticity gene Reelin (Miller & Sweatt 2007). A 
subsequent study demonstrated that knockout of Dnmt1 and Dnmt3a results in 
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abnormal long-term plasticity in the hippocampal CA1 region together with deficits 
in learning and memory (Feng et al. 2010a). In a more recent study it was found that 
25 minutes after a 5 minutes spatial exploration, Arc gene expression increased in 
CA1 while methylation at the promoter decreased and methylation at the intragenic 
region increased (Penner et al. 2011).  
1.1.4. PHARMACOLOGICAL INTERVENTION 
Evidence is emerging that several diseases including psychiatric disorders result 
from defects in gene function (Szyf 2009). These defects may result from DNA 
mutations or from change in epigenetic programming. With pharmaceuticals 
targeting epigenetic mechanisms it is potentially possible to reverse aberrant gene 
expression profiles associated with these disease states (Szyf 2009). In this 
dissertation particular focus is put on schizophrenia and side effects resulting from 
electroconvulsive seizures (ECS). The pharmaceuticals that are described here have 
been selected because of their relevance for these conditions but the background will 
be elaborated in the relevant chapters and not here. Thus, the descriptions below are 
merely functional. 
1.1.4.1. DNMT inhibitors 
The tree most common catalytic inhibitors of DNMTs are the nucleoside analogs 5-
azaC, 5-azaCdR, and zebularine (Szyf 2009). The mechanism by which they inhibit 
DNMTs is common. They are first phosphorylated to a triphosphate nucleotide and 
are subsequently incorporated in DNA during DNA synthesis. During normal DNA 
replication and maintenance methylation of the unmethylated strand, DNMT1 forms 
a covalent bond with the 6’ carbon position of the cytosine ring. DNMT1 then 
transfers a methyl group from the methyl donor S-adenosyl methionine (SAM) to 
the 5’ carbon position of the cytosine ring, whereby the enzyme is released from its 
covalent bond. If 5-azaC has replaced cytosine and been incorporated in DNA, the 
methyl transfer cannot take place and the DNMT is trapped on the DNA (Wu & 
Santi 1985). Replication continues in the absence of DNMT1 and DNA methylation 
patterns are not copied.  
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   The progress described above necessitates that DNA replication takes place. 
Therefore, it was very recently considered surprising that DNMT inhibition was also 
functional in the adult brain (Szyf 2009). However, as described in the sections 
above, the expression of DNMT1 and DNMT3a mRNA is surprisingly high in the 
brain and methylation and demethylation occur rapidly. As the demethylation 
process most likely involves base excision repair this provides a mechanism by 
which 5-azaC may become integrated in DNA allowing subsequent DNMT capture. 
1.1.4.2. HDAC inhibitors 
As described in the previous sections HATs acetylate histones whereas HDACs 
remove acetylation. HDAC inhibitors (HDACi) are considered promising potential 
therapeutics for treatment of psychiatric disorders (Szyf 2009). The commonly used 
mood stabiliser valproate has widespread effects besides functioning as a 
nonspecific class I and II HDAC inhibitor (Göttlicher et al. 2001; Tsankova et al. 
2007).  
   The putative mechanism of HDACi is to tilt the balance of acetylation-
deacetylation resulting in an increase in acetylation. This leads to hyperacetylation 
of histone tails and induction of genes that have previously been repressed (Szyf 
2009). All identified HDACi block one or several classes of HDACs, which should 
consequently influence gene expression globally. However, microarray gene 
expression experiments have revealed that only a part of the transcriptome is 
activated or supressed by HDACi (Dannenberg & Edenberg 2006; Chiba et al. 2004; 
Lee et al. 2004). This is likely because the HDACs and HATs are targeted to 
specific genes and HDACi will only influence genes that are associated with 
HDACs and also targeted by HATs (Szyf 2009). As described in the sections above 
an increase in acetylation can neutralise the positive charge of the lysine and 
destabilises internucleosomal contacts which leads to chromatin decondensation 
(Shogren-Knaak et al. 2006). In addition, HDAC inhibition reduces global DNA 
methylation, DNMT1 protein levels, and its interaction with chromatin (Arzenani et 
al. 2011). The specific mechanisms are unknown. However, HDAC inhibition may 
lead to nucleosome-depleted regions, which prevents DNMT binding and specific 
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histone marks may also directly prevent binding of DNMTs. As transcription from a 
promoter increases this could lead to active promoter demethylation as described in 
the section above. 
1.2. SCHIZOPHRENIA 
Schizophrenia is a debilitating mental disorder with a lifetime risk of approximately 
1% (Sullivan et al. 2012). Morbidity and mortality are high and the condition is 
associated with considerable costs for both affected individuals and society. 
Schizophrenia is not itself fatal but associated with increased risk for suicide as well 
as conditions that adversely affect health such as cardiovascular disease, metabolic 
syndrome, and insulin resistance (Pompili et al. 2008). Schizophrenia most 
commonly presents with delusions and auditory hallucinations late in adolescence or 
in early adulthood (Tandon et al. 2008). Sustained recovery occurs for less than 14% 
within five years following a psychotic episode (Robinson et al. 2004), while the 
long-term outcome is slightly better with an additional 16% with late phase recovery 
within 25 years (Harrison et al. 2001). In Europe less than 20% of individuals 
diagnosed with schizophrenia are employed (Marwaha et al. 2007). These outcomes 
can be improved by early diagnosis and medical intervention (Reser 2007). 
However, our basic understanding of the pathophysiology of schizophrenia is still 
limited and consequently there are no means for curative treatment or prevention 
(Insel 2010). 
1.2.1. SYMPTOMATOLOGY 
Schizophrenia is defined as a syndrome and characterised by a broad and 
heterogeneous symptom spectrum (WHO 1993). Patients typically suffer from three 
categories of symptoms: positive, negative, and cognitive (Nishioka et al. 2012). 
Positive symptoms include illusions, hallucinations, and paranoia. These symptoms 
are believed to result from malfunctional mesolimbic circuits involving nucleus 
accumbens, the main reward and motivation centre of the brain. Negative symptoms 
include anhedonia, lack of motivation, and social withdrawal and have been 
attributed to the prefrontal cortex (Stahl 2013). Cognitive symptoms include a broad 
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variety of deficits, affecting e.g. attention, association, learning, and memory (Coren 
et al. 1984). Consequently cognitive deficits involve a broad range of 
neuroanatomical regions (Henke 2010). As no biomarkers for diagnostic laboratory 
testing exist, the diagnosis is based on clinical assessment of symptoms according to 
the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) 
(A.P.A. 2013).  
 
1.2.2. NEUROPATHOLOGY AND HYPOTHESIS OF SCHIZOPHRENIA 
Despite intensive research the etiology of schizophrenia remains poorly understood. 
Occurrence of schizophrenia before puberty is rare and incidence increases in early 
adulthood (Tandon et al. 2008). The brain continues to develop until this stage and 
may be particularly vulnerable during this period. It is believed that schizophrenia 
may be partly explained by deficits in the course of neurodevelopment and that the 
deficits result from genetic and environmental risk factors (Rapoport et al. 2005; 
Sullivan et al. 2003; Insel 2010). Three major etiologic hypotheses have been 
proposed: the dopamine, the glutamate-gaba, and the neurodevelopmental 
hypothesis:  
   The dopamine hypothesis was based on observations of the psychosis-inducing 
effects of dopamine releasing drugs such as amphetamine, and the anti-psychotic 
efficacy of drugs that block the dopamine D2 receptor (Carlsson 1988). The early 
neuroleptic medications such as chlorpromazine and haloperidol have been replaced 
by “atypical” antipsychotics with fewer extra-pyramidal side effects but treatment 
efficacy has not improved (Lieberman et al. 2005). These antipsychotics reduce 
delusions and hallucinations but have not improved functional recovery, including 
the ability to work (Insel 2010).  
   The glutamate-gaba hypothesis originated from focus on cognitive symptoms. 
This was based on observations that low doses of NMDA receptor antagonists 
resulted in attention and memory problems in healthy individuals (Coyle 2006). The 
theory is that schizophrenia and especially the cognitive symptoms may result from 
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low NMDA receptor activity on GABAergic interneurons in the prefrontal cortex, 
which leads to disinhibition and hyperactivity of cortical pyramidal neurons.  
   The neurodevelopmental hypothesis proposes that developmental insults resulting 
from genetic and environmental risks, results in the emergence of psychosis in late 
adolescence or early adulthood (Insel 2010). More than two decades ago it was 
proposed that schizophrenia is a neurodevelopmental disorder or several disorders 
that involve alterations in brain circuits (Feinberg 1982; Weinberger 1987; Murray 
et al. 1991) and evidence supporting this hypothesis is growing. In most cases 
psychosis occurs between 18 and 25 years of age when the prefrontal cortex is still 
developing. However, our understanding on the normal and abnormal cortical 
development occurring during this period is limited. Neuroimaging studies have 
revealed decreases in grey matter density until mid-twenties and the prefrontal 
cortex is the last to mature (Paus et al. 2008). The cellular basis it not clear although 
post-mortem studies indicate that both synaptic elimination and increased 
myelination continues until this stage (Huttenlocher 1984; Insel 2010). Studies on 
non-human primate brains have revealed that refinement of circuits during early 
adulthood includes pruning of excitatory synapses, and proliferation of inhibitory 
circuits (Rakic et al. 1986; Hashimoto et al. 2009; Lewis & Gonzalez-Burgos 2008). 
Altogether these observations indicate that late stage brain maturation includes a 
calibration of excitatory-inhibitory balance in the cortex (Figure 4). 
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Figure 4. Neurodevelopmental model of schizophrenia. a, normal cortical development 
involves proliferation, migration, arborisation (circuit formation), and myelination. 
Proliferation and migration occur mostly prenatally whereas arborisation and myelination 
continues through the first two postnatal decades. The combined effects are thought to 
account for the progressive reduction of grey-matter volume. Data from human and non-
human primate brain indicate increases in inhibitory and decreases in excitatory synaptic 
strength occurring in prefrontal cortex until early adulthood. These changes occur during the 
period of prodrome and at the time psychosis emergeces. b, the trajectory in children 
developing schizophrenia could include reduction of synapses from inhibitory interneurons in 
the prefrontal cortex and excessive pruning of excitatory pathways in the prefrontal cortex. A 
reduction of myelination could alter connectivity. Modified from (Insel 2010).  
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   In support of the neurodevelopmental hypothesis, longitudinal population based 
studies have revealed that prodromal symptoms are evident long before onset of 
psychosis. It has been reported that adults with schizophrenia have delayed 
developmental milestones within the first year (Sørensen et al. 2010) and that 
children who later developed schizophrenia have reduced IQ (Woodberry et al. 
2008; Reichenberg et al. 2010). Post-mortem studies have consistently reported a 
loss of GABA and reductions in enzymes responsible for glutamate biosynthesis, but 
these changes may represent the consequences of chronic illness or treatment, rather 
than the cause of schizophrenia (Coyle 2006). The challenges of separating cause 
and effect can be overcome by genetic analysis. 
 
1.2.3. GENETIC RISK FACTORS 
The strongest single predictor for risk of developing schizophrenia is familial history 
(Hallmayer 2000). Based on twin, family, and adoption studies the heritability of 
schizophrenia has been estimated to be 64% and 81%, respectively in two separate 
meta-analyses (Lichtenstein et al. 2009; Sullivan et al. 2003). The risk for 
schizophrenia has been estimated to be 46% when both parents have schizophrenia 
and the concordance rate for monozygotic twins is 48% (Gottesman 1990). These 
results are consistent with the view of schizophrenia as a complex trait that results 
from genetic and environmental etiological influences. The genetic studies initially 
included linkage studies, candidate gene association studies and assessments of 
larger structural variants. More recently, GWAS was introduced and accounts for an 
increasing number of studies. Family, linkage, and case-control studies have 
revealed genes including COMT, DTNBp1, NRG1, RGS4, GRM3, G72, PP3CC, 
CHRNA7, and PRODH as being risk factors for schizophrenia (Badner & Gershon 
2002; Harrison & Weinberger 2005; Lewis et al. 2003; Munafò et al. 2006; Ng et al. 
2009). GWAS have identified genes such as ZNF804A, TCF4, NRGN, and MIR137 
(O’Donovan et al. 2008; Purcell et al. 2009; Ripke et al. 2011; Shi et al. 2009; 
Stefansson et al. 2009). 
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   It has been debated whether genetic risk for schizophrenia is caused by interaction 
of several common variants each of very small effect (common disease – common 
variant model, (Purcell et al. 2009)) or by rare but highly penetrant genetic variants 
(common disease – rare variant model, (Stone et al. 2008)). In a recent GWAS 
analysis it was estimated that approximately 8300 independent SNPs contribute to 
risk (Ripke et al. 2013). However, such studies only include relatively common 
SNPs, and future next generation sequencing studies could potentially reveal rare 
SNPs, insertions or deletions of higher effect sizes.  
   Recently, a combined meta-analysis of 18 GWAS ensued by a family-based 
replication study of schizophrenia risk genes, identified the BRD1 promoter SNP 
rs138880 as the variant showing the most significant association with the disease 
(Aberg et al. 2013). This augments previous studies linking rs138880 with both 
schizophrenia and bipolar disorders in large Caucasian case-control samples 
(Nyegaard et al. 2010; Severinsen et al. 2006) as well as the previous identification 
of a susceptibility locus containing BRD1 in the Faroese population (Jorgensen et al. 
2002). The function of BRD1 and its possible implications in schizophrenia will be 
further described in upcoming sections.  
   Genetic linkage to the CHRNA7 gene was first found to an endophenotype in 
schizophrenia, the P50 deficit (Freedman et al. 1997) and then to the disease itself. 
The CHRNA7 gene, encoding the α7 nAChR, is located at chromosome 15q13.3, a 
region that has been identified as a candidate risk loci for schizophrenia (Leonard & 
Freedman 2006). SNPs in the promoter region of CHRNA7 show significant 
association with schizophrenia (Stephens et al. 2009). The function of CHRNA7 and 
its possible implications in schizophrenia will be further described in upcoming 
sections. 
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1.2.4. ENVIRONMENTAL RISK FACTORS 
Epidemiological studies have established that certain environmental factors are 
associated with increased risk of schizophrenia. These risk factors are generally 
divided as early (prenatal until gestation) and late (childhood and early adulthood). 
The early risk factors for later development of schizophrenia include: Pre-natal virus 
infections, greater parental age, reduced nutrition, low socioeconomic class, urban 
birth, winter birth, premature birth, and delivery-related hypoxia (Brown et al. 2010; 
Perrin et al. 2007; Torrey et al. 1997; Nishioka et al. 2012). The late risk factors 
include: Social stress, childhood abuse, urbanicity, migration, and cannabis abuse 
(van Winkel et al. 2008; Fisher et al. 2014; Pedersen & Mortensen 2001; Cantor-
Graae & Selten 2005; Moore et al. 2007). The early phase risk factors are very likely 
to affect normal neurodevelopment whereas the late factors may be particularly 
important for predisposed individuals. 
1.2.5. EPIGENETIC REGULATION IN PSYCHIATRIC DISORDERS 
A possible role of DNA methylation in the pathogenesis of schizophrenia was 
suggested decades ago after clinical studies revealed that treatment with the methyl-
donor SAM elicited psychotic episodes in some patients with schizophrenia (Antun 
et al. 1971). Postmortem studies have revealed that DNA methylation changes are 
present in brains of schizophrenics. Studies have reported hypermethylation of the 
Reelin promoter and downregulation of expression in several brain regions 
(Abdolmaleky et al. 2005; Grayson et al. 2005). Reelin is a glycoprotein that is 
expressed during development and in adult GABAergic neurons and is important for 
proper neural positioning during brain development. In addition, methylation 
changes have been reported for COMT (Abdolmaleky et al. 2006) and SOX10 
(Iwamoto et al. 2005). One of the challenges with post-mortem studies is that the 
changes may represent the consequences of chronic illness or treatment, rather than 
the cause of schizophrenia (Coyle 2006). Nevertheless, reversal of such changes 
could be important for relieving symptoms and could be possible with 
pharmaceuticals targeting epigenetic mechanisms, as described above. 
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   Epigenetic changes may also result from genetic alterations and as described 
above the number of schizophrenia-associated genomic loci is growing. The 
majority of these GWAS-identified markers do not directly alter protein sequence 
but seem more important for regulating gene expression, as disease-associated 
variants affect transcription factor recognition sequences and frequently alter allelic 
chromatin states (Maurano et al. 2012). In human brain samples it has been 
established that methylation of a high number of CpG sites show significant cis 
associations with SNPs and a lower number show significant trans associations 
(Zhang et al. 2010a). For the schizophrenia associated DRD4 gene four SNPs 
showed significant associations with DNA methylation (Docherty et al. 2012).  
   In a recent study, methylomic variation was profiled in prefrontal cortex from 
schizophrenia patients and controls (Pidsley et al. 2014). Disease-associated 
differential DNA methylation was identified at multiple loci. Importantly, the loci 
co-localize with genes important for neurodevelopment and genes that have been 
genetically linked with schizophrenia. In addition, the schizophrenia-associated 
differentially methylated positions were enriched for loci at which DNA methylation 
is dynamically regulated during human fetal brain development (days 23-184 post-
conception). Thus, genetic variants could potentially lead to altered gene expression 
in a mechanism involving epigenetic regulation. 
 
1.2.6. CANDIDATE GENES 
Much effort is put into identification of risk factors for schizophrenia and twin and 
adoption studies have demonstrated a clear inherited component (Ripke et al. 2014). 
The SNPs associated with schizophrenia that have been identified in GWAS are 
statistically significantly associated with the disorder but mechanistic studies are 
needed to reveal their functional contribution to pathogenesis. Generally, the 
identified markers seem to be more important for regulating gene expression rather 
than direct alteration of protein sequence (Maurano et al. 2012). In this dissertation 
particular attention is given to BRD1 and CHRNA7, two genes that are associated 
with the disease but whose mechanisms are very different.  
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1.2.6.1. BRD1 
BRD1 encodes the bromodomain-containing protein 1 (BRD1), a transcription factor 
widely expressed in human tissues including the brain, that has been identified in 
protein complexes possessing acetyltransferase activity specific for histone H3 
(Doyon et al. 2006; Mishima et al. 2011). BRD1 has been found to bind in several 
genomic regions including promoter regions and to regulate expression of a large 
number of genes (Fryland et al., manuscript submitted). Importantly, a high number 
of these genes are schizophrenia risk genes and the majority are part of signalling 
pathways important for neurodevelopment, emphasising the possible involvement of 
BRD1 in a polygenic disease such as schizophrenia. BRD1 is important in 
embryogenesis as knockout of Brd1 in mice leads to impaired eye development and 
neural tube closure and ultimately a lethal maturation defect in embryonic 
hematopoiesis (Mishima et al. 2011). Adult Brd1+/- mice display dysregulated 
cerebral gene expression, behavioural abnormalities translating to the major 
hallmarks of schizophrenia, and neurochemical alterations involving dopamine 
levels and glutamate and GABAergic signalling (Qvist et al., manuscript submitted). 
In the developing fetal pig brain BRD1 is highly expressed at early embryonic stages 
and expression then declines in the later stages (Severinsen et al. 2006). An 
important role for BRD1 in the adult brain is suggested by regulation after both ECS 
(Fryland et al. 2012) and chronic restraint stress (Christensen et al. 2012). Notably, 
Brd1 mRNA and protein is upregulated in the hippocampus following 21 days of 
chronic restraint stress in rats, suggesting involvement in regulatory processes 
underlying adaptation to stress in the mature CNS. Thus, with the overall functions 
of BRD1, dysregulation of the gene could result in neurodevelopmental deficits. 
1.2.6.2. CHRNA7 
The CHRNA7 gene, encoding the α7 nAChR, is located at chromosome 15q13.3, a 
region that has been identified as a candidate risk loci for schizophrenia (Leonard & 
Freedman 2006). SNPs in the promoter region of CHRNA7 show significant 
association with schizophrenia (Stephens et al. 2009) and several rare promoter 
SNPs decrease promoter activity (Leonard et al. 2002). Notably, these promoter 
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SNPs are associated with failure to inhibit the P50 auditory evoked potential 
response, a deficit that is found in most schizophrenics and 50% of their first-degree 
relatives (Leonard et al. 2002). The α7 nAChR is a homopentameric ligand-gated 
channel with high permeability for Ca2+ that presynaptically increases 
neurotransmitter release from specific terminals and postsynaptically affects gene 
expression (Albuquerque et al. 2009; Araud et al. 2011). The receptor is widely 
distributed in human tissues including the brain (Albuquerque et al. 2009; Dani & 
Bertrand 2007).  
   Estimated 80% of schizophrenics are smokers and an idea of using the α7 nAChR 
as a target for treatment of cognitive dysfunction arose when smoking was 
discovered to normalise sensory processing deficits in schizophrenic patients (Adler 
et al. 1993; Olincy et al. 1998; Leonard et al. 2007) and improve cognitive deficits 
(Levin et al. 2006; Rezvani & Levin 2001). The α7 nAChR is now considered a 
promising drug target for treatment of cognitive dysfunction (Thomsen et al. 2010; 
Wallace & Porter 2011) and α7 nAChR agonists have been reported to produce 
improvements in memory and executive functions in both schizophrenics and 
healthy volunteers (Preskorn et al. 2014; Kitagawa et al. 2003; Freedman et al. 2008; 
Olincy et al. 2006).  
 
1.3. DEPRESSION 
Major depressive disorder is characterised by one or more major depressive episodes 
and has a lifetime prevalence of more than 16% for the general population (Kessler 
et al. 2003). The disease accounts for 12.1% of total years lived with disability and 
remains a major health problem worldwide (Ustün et al. 2004). Patients present with 
rather variable symptoms such as: depressed mood, anhedonia, feelings of guilt or 
low self-worth, poor concentration, and disturbances in sleep and appetite (Nestler et 
al. 2002). Accordingly, depression should be considered a heterogeneous syndrome 
comprised of numerous diseases of distinct causes and pathophysiologies.  
   While our understanding of pathophysiology is still limited, it is well established 
that genetic and environmental factors are important players in vulnerability for 
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depression (Nestler et al. 2002). The genetic contribution has been estimated to be 
37% (Sullivan et al. 2000). Common environmental influences have very small 
effects, while individual-specific environmental influences was estimated to be 63% 
(Sullivan et al. 2000). Although there have been several reports of genetic variants 
associated with major depression (López-León et al. 2008; van Rossum et al. 2006; 
Wray et al. 2012), the findings have been difficult to replicate. In a recent mega-
analysis of GWAS for major depressive disorder there were no robust and replicable 
findings (Ripke et al. 2013). This is most likely because the high prevalence of 
major depressive disorder causes the sample to be underpowered to detect genetic 
effects typical for complex traits (Ripke et al. 2013).  
   Both genetic variation and environmental factors are known to influence 
epigenetic mechanisms (Klengel et al. 2014). By investigating epigenetic changes it 
may be possible to get an integrated view of how genetic and environmental factors 
alter risk (Menke & Binder 2014). There have been several findings of epigenetic 
changes related to depression and particularly exposure to stressful early life events 
have been studied. Early life stress is associated with increased DNA methylation 
levels in the promoter region of NR3C1, encoding the glucocorticoid receptor 
(Perroud et al. 2011; McGowan et al. 2009; Melas et al. 2013). Normally 
glucocorticoid receptors on neurons in the hippocampus and paraventricular nucleus 
of the hypothalamus exert negative feedback to the hypothalamic–pituitary–adrenal 
axis and it has been suggested that hypermethylation and reduced gene expression 
could lead to increased cortisol levels in stressful situations (Perroud et al. 2011). 
The serotonin transporter gene SLC6A4 has also been extensively studied. It has 
been found that stressful job situations are associated with decreased promoter 
methylation (Alasaari et al. 2012) whereas in depressed patients increased promoter 
methylation is associated with childhood adverse events and worse clinical 
presentation (Kang et al. 2013a). In addition, a study of monozygotic twins revealed 
that promoter methylation was positively correlated with depressive symptoms 
(Zhao et al. 2013). BDNF has also been extensively studied. BDNF is a neurotrophin 
and is involved in processes such as proliferation, migration, differentiation, and cell 
survival (Huang & Reichardt 2001). BDNF is particularly interesting due to its 
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strong association with depression and its induction by antidepressants (Murphy et 
al. 2013). Increased methylation of the BNDF promoter has been associated with 
suicidal attempt history (Kang et al. 2013b) and the same has been observed in post-
mortem brain samples (Keller et al. 2010).  
   Current pharmaceutical treatments are only effective in approximately 60-65% 
patients and require long-term administration to achieve therapeutic effects (Schloss 
& Henn 2004). The clinical efficacy of ECT ranges from 85-90%, and generally also 
requires repeated administration (Schloss & Henn 2004). The slow onset of 
therapeutic effects suggests that long term adaptions are required and these might 
involve epigenetic regulation. The high therapeutic efficacy of ECT has triggered a 
large number of studies attempting to identify new drug targets. These studies have 
not resulted in identification of new therapeutic mechanisms and consequently the 
treatment is still widely used. Unfortunately, ECT is also associated with adverse 
effects and these are also being intensively studied.  
1.3.1. ECS: NEURONAL DEPOLARISATION AND GENE EXPRESSION 
Electroconvulsive therapy (ECT) remains one of the most effective treatments of 
severe depression (Berton & Nestler 2006). Clinical efficacy ranges from 85-90%, 
whereas for pharmaceutical antidepressants it is only 60–65% (Schloss & Henn 
2004). Electroconvulsive stimulation (ECS), an animal model of ECT, causes a 
widespread release of neurotransmitters, which affects a variety of transporters and 
receptors in the brain (Schloss & Henn 2004). The therapeutic mechanism likely 
involves cellular changes, including increased neurogenesis, increased cell 
proliferation, fiber sprouting, and enhanced synaptic signalling all of which have 
been observed after ECS (Schloss & Henn 2004). Such changes have been 
suggested to be orchestrated at the level of gene expression and the first studies of 
ECS-induced gene expression were published decades ago (Leviel et al. 1990; 
Winston et al. 1990; Xie et al. 1989; Zawia & Bondy 1990). It has been speculated 
that chromatin remodelling at gene promoter regions can mediate acute and chronic 
effects on gene activity (Tsankova et al. 2004). 
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   Unfortunately, adverse effects such as cognitive and memory deficits have been 
reported after ECT, making it the last option only when pharmaceutical 
antidepressants are ineffective (Fava & Kendler 2000). Expression of immediate 
early genes (IEGs), including Arc is important in regulating neuronal plasticity 
during memory formation and consolidation (Abraham et al. 1994; Guzowski et al. 
2000; Bramham et al. 2009). In cortical neurons the transcription of Arc is tightly 
coupled to stimuli triggering neuronal depolarisation (Link et al. 1995; Lyford et al. 
1995). Arc mRNA accumulates at the dendritic arbor of stimulated neurons and 
translation of ARC protein occurs specifically at active synapses (Link et al. 1995; 
Lyford et al. 1995; Wallace et al. 1998; Bagni et al. 2000).  
    In mice, ECS causes rapid active DNA demethylation or de novo methylation at a 
high number of CpG sites in dentate granule neurons (Guo et al. 2011b). Pre-
treatment of the mice with a highly selective NMDA receptor antagonist abolished 
ECS-induced changes, which confirm that these epigenetic changes are neuronal 
activity-dependent. In addition, infusion of DNMT inhibitors abolishes activity-
induced de novo methylation with no obvious effect on demethylation. Combined 
with the knowledge described above about the importance of DNA methylation in 
memory formation, this observation emphasises that DNA methylation could cause 
memory deficits following ECT. 
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2. OBJECTIVES 
This research aimed to investigate the involvement of DNA methylation in etiology 
and treatment of psychiatric disorders.  
Study I aimed to evaluate, 
• The potential role of DNA methylation in regulating BRD1 transcription. 
• Possibility of modulating transcription by DNMT inhibition. 
• The influence of SNP rs138880 on transcriptional regulation. 
• The effect of common mood stabilisers on BRD1 transcription.  
Study II aimed to evaluate, 
• The potential role of DNA methylation in regulating CHRNA7 transcription. 
• Possibility of modulating transcription by HDAC inhibition 
• Involvement of DNA methylation in CHRNA7 regulation in-vivo 
Study III aimed to evaluate, 
• Spatiotemporal profiles of Arc and c-Fos protein expression 
• Epigenetic regulation of Arc and c-Fos 
Study IV aimed to evaluate, 
• The temporal gene expression profiles for several target genes after acute 
electroconvulsive stimulation  
• (This study was primarily set up for investing Arc, Dnmt1 and Dnmt3a 
expression for use in study V). 
Study V aimed to evaluate, 
• The temporal gene expression profiles for Arc, Dnmt1, and Dnmt3a after acute 
electroconvulsive stimulation  
• The potential of blocking DNMT activity in order to prevent de novo 
methylation of Arc. 
• DNA methylation of the Arc promoter and intragenic region at a timepoint later 
than previously observed (48 hours instead of 24 hours) after acute 
electroconvulsive stimulation 
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4. RESULTS 
STUDY I 
 
DNA methylation regulates BRD1 and is increased by the schizophrenia 
associated SNP rs138880 
 
Mads Dyrvig, Per Qvist, Jacek Lichota, Knud Erik Larsen, Mette Nyegaard, Anders 
D. Børglum, and Jane H. Christensen 
 
This manuscript is in preparation
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STUDY II 
 
DNA methylation regulates CHRNA7 transcription in human cortical tissue 
and can be modulated by HDAC inhibitor valproate in human cell lines 
 
Mads Dyrvig, Jens D. Mikkelsen, and Jacek Lichota 
 
This manuscript is in preparation 
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STUDY III 
 
Epigenetic regulation of Arc and c-Fos in the hippocampus after acute 
electroconvulsive stimulation in the rat 
 
Mads Dyrvig, Henrik H. Hansen, Søren H. Christiansen, David P.D. Woldbye, Jens 
D. Mikkelsen, Jacek Lichota 
 
This manuscript is published in: Brain Research Bulletin 88 (2012) 507–513 
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a  b  s  t  r  a  c  t
Electroconvulsive  stimulation  (ECS)  remains  one  of the  most  effective  treatments  of  major  depression.
However,  the underlying  molecular  changes  still  remain  to be elucidated.  Since  ECS  causes  rapid  and  sig-
nificant  changes  in  gene  expression  we  have  looked  at epigenetic  regulation  of  two  important  immediate
early  genes  that  are  both  induced  after  ECS:  c-Fos  and  Arc.  We  examined  Arc  and  c-Fos  protein  expression
and  found  Arc  present  over  4 h,  in contrast  to c-Fos  presence  lasting  only  1  h.  Both  genes  had  returned  to
baseline  expression  at  24  h  post-ECS.  Histone  H4  acetylation  (H4Ac)  is one  of the important  epigenetic
marks  associated  with  gene  activation.  We  show  increased  H4Ac  at  the  c-Fos  promoter  at 1 h post-ECS.
Surprisingly,  we  also  observed  a  significant  increase  in  DNA  methylation  of  the  Arc  gene  promoter  at 24  h
post-ECS.  DNA  methylation,  which  is  responsible  for  gene  silencing,  is  a  rather  stable  covalent  modifica-
tion.  This  suggests  that  Arc  expression  has  been  repressed  and  may  consequently  remain  inhibited  for  a
prolonged  period  post-ECS.  Arc  plays  a  critical  role  in  the  maintenance  phase  of long-term  potentiation
(LTP)  and  consolidation  of  memory  in  the rat  brain.  Thus,  this  study  is  one  of the  first  to  demonstrate
DNA  methylation  as a regulator  of  ECS-induced  gene  expression  and  it  provides  a  molecular  link  to the
memory  deficits  observed  after  ECS.
© 2012 Elsevier Inc. All rights reserved.
1. Introduction
Electroconvulsive therapy (ECT) represents one of the most
effective treatments against severe depression (Berton and Nestler,
2006). The mechanism of action may  involve gene expression and
it has been speculated that chromatin remodeling at gene pro-
moter regions mediate acute and chronic effects on gene activity
after electroconvulsive stimulation (ECS) (Tsankova et al., 2004), an
experimental model of ECT. Some of the affected genes and their
associated epigenetic modifications may  be beneficially involved
in recovery whereas others may  be adverse. So far little atten-
tion has been paid to the identification and alleviation of adverse
effects associated with the treatment, the most prominent of which
are negative effects on memory and cognitive functions (Fava and
Kendler, 2000).
∗ Corresponding author at: Laboratory of Neurobiology, Aalborg University,
Fredrik  Bajers Vej 3B, DK-9220 Aalborg Øst, Denmark. Tel.: +45 99407461;
fax: +45 9635 7816.
E-mail  address: jlichota@hst.aau.dk (J. Lichota).
DNA methylation and histone modifications play an important
role in setting up either permissive or repressive environments for
transcriptional machinery (Dulac, 2010). The histone code hypoth-
esis suggests that specific modifications of one or more histone
tail residues at particular promoter regions are read sequentially
or summed up, thereby defining the epigenetic state of the gene
(Jenuwein and Allis, 2001). Histone acetylation, especially histone
H4 (H4Ac), is a hallmark of an open, transcriptionally active chro-
matin (Renthal et al., 2007). In addition, H4Ac has previously been
found to correlate well with the expression of c-Fos, Bdnf, and
Creb mRNA at several time points after acute and chronic ECS
(Tsankova et al., 2004). While histone acetylation is a modifica-
tion that can be dynamically regulated in the CNS (Levenson et al.,
2004), DNA methylation has been thought to be involved in set-
ting up transcriptional landscapes only in mitotically active cells.
However, there is growing evidence that DNA methylation is a very
dynamic modification in the CNS (Feng et al., 2010; Levenson et al.,
2006; Martinowich et al., 2003; Miller and Sweatt, 2007). Unlike
other post-mitotic cells, neurons express DNA methyltransferase 1
(DNMT1) and this enzyme is involved in DNA repair, neurodegener-
ation (Brooks et al., 1996; Endres et al., 2000, 2001; Fan et al., 2001)
and cognitive disorders such as schizophrenia, Rett syndrome and
0361-9230/$ – see front matter ©  2012 Elsevier Inc. All rights reserved.
http://dx.doi.org/10.1016/j.brainresbull.2012.05.004
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Fragile X mental retardation (Amir et al., 1999; Sutcliffe et al., 1992;
Veldic et al., 2004).
Expression  of immediate early genes (IEGs), including activity-
regulated cytoskeleton-associated protein (Arc also known as
Arg3.1) and c-Fos play important roles in regulating neuronal plas-
ticity during memory formation and consolidation (Abraham et al.,
1994; Bramham et al., 2009; Kaczmarek, 1992). Arc was initially
identified in cortical neurons as an IEG with its transcription being
tightly coupled to stimuli triggering neuronal depolarization (Link
et al., 1995; Lyford et al., 1995). While many IEGs serve specif-
ically as transcription factors, Arc mRNA is accumulated at the
dendritic arbor of stimulated neurons (Link et al., 1995; Lyford et al.,
1995; Wallace et al., 1998). Thus, translation of the Arc protein is
specifically targeted to occur at active synapses (Bagni et al., 2000;
Wallace et al., 1998), which is considered the molecular basis for
Arc-mediated long-term synapse-specific modifications (Rodríguez
et al., 2005). Notably, Arc mRNA is also induced in hippocam-
pal and neocortical neurons after behavioral learning paradigms
and Arc protein expression plays a critical role in the mainte-
nance phase of long-term potentiation (LTP) and consolidation
of memory in the rat brain (Guzowski et al., 2000). Simi-
larly, c-Fos knockout mice display defects in long-term memory
(Fleischmann et al., 2003).
Both Arc and c-Fos expression are increased in the hippocampal
formation following ECS (Larsen et al., 2005; Lyford et al., 1995;
Steward and Worley, 2001; Wallace et al., 1998; Woldbye et al.,
1996). Interestingly, we previously found reduced Arc gene expres-
sion in the dentate gyrus 24 h after acute ECS and in the CA1 24 h
after chronic ECS (Larsen et al., 2005), brain regions that are cen-
trally involved in memory consolidation (Ramirez-Amaya, 2005).
Considering the importance of Arc mRNA and protein in networks
that underlie information processing and memory, this decrease
might represent a molecular cause of memory and learning deficits,
observed in rats as a consequence of ECS (Andrade et al., 2011;
Luo et al., 2011; Yao et al., 2010). Similarly, deficits in memory
are seen in depressed patients undergoing ECT. In this report, we
explored epigenetic regulation of hippocampal Arc and c-Fos as well
as spatiotemporal profile changes of both proteins following acute
ECS.
2. Materials and methods
2.1.  Animals and treatment
Adult  male Sprague-Dawley rats (270–290 g, Charles River Laboratories, Ham-
burg,  Germany) were used. All experiments were conducted in accordance with
guidelines of the National Institute of Health (NIH Publications No. 85-23, 1985)
and  the Animal Experimentation Inspectorate, Ministry of Justice, Denmark. Animals
were given a single ECS via ear clip electrodes (50 mA,  0.5 s, unidirectional square
wave  pulses; (Woldbye et al., 1996)). Sham animals were handled similarly but with-
out  the passing of current. The experiment was  terminated following a described
post-ECS  period for in situ hybridization and histochemical analyses (1 h, 4 h, 24 h),
for  ChIP and DNA methylation analyses (1 h and 24 h), and for immunohistochemical
analyses  (10 min, 1 h, 4 h, 8 h, 24 h).
2.2.  In situ hybridization
In situ hybridization was  performed as described previously (Larsen et al., 2005)
using synthetic oligonucleotide DNA probes complimentary to the rat Arc (targeting
bases  789–839 (Pei et al., 2004)) and c-Fos (targeting bases 133–180 (Madsen et al.,
1999)) (DNA Technology, Aarhus, Denmark). The sections were dried and exposed
together  with 14C standards to a Kodak BiomaxMR film (Sigma Aldrich) for 2 weeks.
Optical densities were quantified in the granular cell layer and molecular layer using
a  computer image analysis system (QuantityOne v.4.5.2, BioRad, Hercules, CA). The
definition of these areas was based on well-defined landmarks in the same section,
in particular in sections with low level of expression in animals 24 h post-ECS. The
individual value for each animal was the average of three individual sections mea-
sured bilaterally within the areas of interest. Data were analyzed using one-way
ANOVA  followed by Newman Keul’s post hoc test.
2.3. Chromatin immunoprecipitation (ChIP)
Dissected hippocampi were chopped into smaller pieces, transferred to
an  Eppendorf tube and subsequently incubated 15 min  on ice in 1.5 mL 1%
paraformaldehyde/PBS.  The crosslinking procedure was terminated by addition
of  125 mM glycine for a minimum of 5 min, then followed by 4 washes in
750  !L PBS with protease inhibitors (Complete Protease Inhibitor Cocktail (Roche,
Switzerland)).  The ChIP assay was performed as described previously (Tsankova
et  al., 2004) with minor modifications. The samples were split into 600 !L chromatin
portions.  6 !L antibody directed against H4 acetylated at Lys5, Lys8, Lys12, and Lys16
(Upstate #06-866) was  added. For mock control, rabbit serum was  used. The samples
were incubated overnight at 4 ◦C with gentle agitation. The immune complexes were
collected using 50 !L blocked Dynabeads® Protein A by incubating for 3 h at 4 ◦C with
gentle agitation. The beads were collected by magnetic force, washed once with
1 mL for 10 min  with each of these buffers: low salt buffer (150 mM NaCl, 1% SDS, 1%
triton X-100, 2 mM EDTA, 20 mM HEPES pH 8), 1 mL high salt buffer (like low-salt
but  500 mM NaCl), 1 mL  LiCl wash buffer (0.25 M LiCl, 1% NP-40, 1% sodium deoxy-
cholate, 1 mM EDTA, 10 mM HEPES pH 8) and twice with 1 mL TE buffer (10 mM
Tris–HCl pH 8, 1 mM EDTA). The immune complexes were eluted twice with 250 !L
elution buffer (1% SDS, 0.1 M NaHCO3) for 15 min, 65 ◦C. The cross linking was
reversed  by addition of 20 !L 5 M NaCl, 12 h at 65 ◦C. DNA was purified by ChIP DNA
Clean  & ConcentratorTM (Zymo Research, USA) according to manufacturer’s protocol.
All  PCR amplifications were performed in 20 !L reaction volume using SYBR-Green
Brilliant  II master mix  (Stratagene, USA). Following program was used: 95 ◦C 10 min,
40  cycles: 95 ◦C 30 s, 60 ◦C 30 s. The relative quantities of DNA in the analyzed sam-
ples were calculated by the Pfaffl method (Pfaffl, 2001). The primers to amplify
the  Arc promoter, c-Fos promoter and the control housekeeping gene Beta-actin
were: Arc fwd  GACAAGGCAGAGGAGAGTGTC, Arc rev CCGGAGTGACTAATGTGCTCT,
c-Fos  fwd TTCTCTGTTCCGCTCATGACGT, c-Fos rev CTTCTCAGTTGCTAGCTGCAATCG,
Beta-actin fwd  GTGGCACCACCATGTACCCAGGCAT, Beta-actin rev ACTACAGGGCT-
GACCACACCCCACT  for each primer set applied, the immunoprecipitated samples
were amplified on the same plate and all determination was  carried out in tripli-
cates  in one qPCR run. Data were normalized with the house-keeping gene Beta-actin
and  analyzed by GraphPad Prism software using unpaired t-test.
2.4.  DNA methylation analysis
Hippocampal DNA was extracted with a DNeasyBlood & Tissue kit (Qiagen,
Germany),  following manufacturer’s instructions for purification of total DNA from
animal tissues (Spin-Column Protocol). All DNA samples were bisulfite converted
with an EpiTect® Bisulfite kit (Qiagen), according to the manufacturer’s proto-
col  for sodium bisulfite conversion of unmethylated cytosines. 10 !L of bisulfite
converted  DNA was used as template in a 20 !L PCR reaction mixture with the
following  primers: c-Fos fwd TAATTGTGAATATTTATAGGTGAAAGTTAT, c-Fos rev
ACTCTATCCAATCTTCTCAATTACTAA, Arc fwd  GGAGAGTGTTTTTGGTTTTTAAGATT,
Arc  rev CTCAAACTAAAAAAACCCAAAAACTA. TrueStart polymerase (Fermentas,
Lithuania)  was  used in the following PCR program: 95 ◦C for 5 min, followed by 35
cycles of 95 ◦C for 1 min, 55 ◦C for 2:30 min, 68 ◦C for 1 min, and a final step of 68 ◦C
for 5 min. PCR products were isolated from agarose gel with a NucleoSpin® Extract II
Kit  (Macherey-Nagel, Germany) and cloned using the InsTAcloneTM PCR Cloning Kit
(Fermentas, Lithuania). Selected plasmid DNA were extracted with a NucleoSpin®
Plasmid kit (Macherey-Nagel, Germany) and 1.5 !g of each prep was freeze-dried
and  sent to Beckman Coulter Genomics (United Kingdom) for sequencing. Data were
analyzed by GraphPad Prism software using one-way ANOVA with Newman Keul’s
post hoc test.
2.5.  Western blotting
The polyclonal Arc antibody (Thomsen et al., 2008) was validated on western
blotting.  Samples were homogenized in a lysis buffer (137 mM NaCl, 20 mM Tris, 1%
NP-40, 10% glycerol, 48 mM NaF, H2O, 2× complete inhibitor cocktail (Roche, Indi-
anapolis, IN) and 2 mM Na2VO3), incubated on ice (>15 min), centrifuged (16,100 × g,
15  min) and the supernatants collected. Samples (50 !g total protein) were sepa-
rated  by 4–12% gradient SDS-PAGE and western blotting was performed using Arc
antisera (1:1000–2000). Specifically bound antibody was detected by incubation
with  either alkaline phosphatase or horseradish peroxidase-conjugated (1:50,000;
GE  Healthcare, Piscataway, NJ) anti-rabbit antibody, respectively.
2.6.  Immunohistochemical analysis
Rats  were deeply anaesthetized with pentobarbital (mebumal 50 mg/mL,
3.0  mL/kg, SAD, Copenhagen, Denmark) and perfused transcardially with PBS fol-
lowed by 4% paraformaldehyde in 0.1 M phosphate buffer for 10 min. The forebrains
were immersed in fixative overnight and subsequently submerged in 30% sucrose
in PBS at 4 ◦C for three days. 40 !m serial coronal sections were cut through the
forebrain  in series of five on a freezing microtome and representative sections were
processed for c-Fos immunoreactivity. The sections were rinsed for 3× 10  min in
0.01 M PBS, incubated for 10 min  in 1% H2O2–PBS to block endogenous peroxidase
activity,  and for a minimum of 20 min  in 0.01 M PBS with 0.3% Triton X-100 (TX), 5%
swine serum, and 1% bovine serum albumin (BSA) to block non-specific binding sites.
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The  sections were then incubated at 4 ◦C for 24 h in the primary antiserum diluted
1:1000  (Arc; #8541 bleed 3) or 1:4000 (c-Fos), respectively, in 0.01 M PBS with 0.3%
Triton X-100 and 1% BSA. After incubation in primary antibody, immunoreactivity
was  detected by the avidin–biotin method using diaminobenzidine as chromagen.
The  sections were washed in 0.01 M PBS with 0.1% TX (PBS-TX), and incubated for
60 min  in biotinylated donkey anti-rabbit (Jackson Laboratories, Ben Harbor, ME)
diluted 1:2000 (for Arc) or 1:4000 (for c-Fos), respectively, in PBS-TX with 0.3% BSA,
washed again and transferred to the avidin–biotin ABC complex (Vector Laborato-
ries,  Burlingame, CA) diluted 1:250 in PBS-TX and 0.3% BSA. After a careful wash
in  PBS-TX, and in Tris–HCl (pH 7.6) for 2× 10 min, the sections were incubated in
0.05% diaminobenzidine (Sigma, St. Louis, MI,  USA) with 0.05% H2O2 in Tris–HCl
buffer  for 10 min  and then washed twice in PBS buffer. The sections were mounted
on  gelatinized glass slides, dried, and coverslipped in Pertex.
3. Results
To confirm our previous findings (Larsen et al., 2005; Woldbye
et al., 1996) we initially used in situ hybridization histochemical
analysis of Arc and c-Fos mRNA expression. For Arc this confirmed
expression in the granule cell layer seen up to 4 h after the strong
stimulus. As reported earlier (Link et al., 1995), Arc mRNA was
detected not only over the soma of the granule cell layers, but also
in the molecular layer reflecting the translocation to the dendrites
of these cells. For c-Fos, the expression of mRNA peaked at 1 h and
declined to sham levels at 4 h (Sup. Fig. 1).
3.1.  Histone H4 acetylation (H4Ac) at Arc and c-Fos promoters
The  ChIP assay was  performed on chromatin isolated from
hippocampus 1 h and 24 h post-ECS and compared to chromatin
extracted from hippocampus from rat under sham conditions.
Regulation of H4Ac levels of the specific DNA fragments were calcu-
lated after qPCR as the ratio of normalized mean quantities for the
ECS samples to the normalized mean quantity of the sham samples
from each set of animals. As for the c-Fos promoter, a significant
increase in H4Ac was found 1 h post-ECS, with a return to sham
levels 24 h after ECS (Fig. 1A). In contrast, the Arc promoter showed
no significant changes in H4Ac at any time point investigated, sug-
gesting that this modification is not involved in transcriptional
activation of Arc (Fig. 1B).
3.2.  DNA methylation of Arc and c-Fos Promoters
Promoter DNA methylation, another epigenetic factor influenc-
ing gene expression, was  investigated. DNA isolated from the same
set of animals (1 h and 24 h post-ECS and corresponding sham) was
subjected to bisulfite conversion. The proximal promoter region of
c-Fos ranging from nucleotides −163 until +16 comprised 12 CpG
sites that can potentially be methylated. Investigation of the c-Fos
promoter revealed hypomethylation at these sites for sham con-
trols as well as for ECS-treated animals at both 1 h and 24 h post-ECS
(data not shown).
The  promoter region of the Arc gene, ranging from −242 to +31,
comprising 30 CpG sites (Fig. 2A), was likewise analyzed for DNA
methylation in all groups. We  analyzed 60 clones for each groups of
animals and the percentage of methylated clones in each group was
compared. Clones with one or more methylated sites were counted
as “methylated,” and each value was divided by the total number
of clones. Interestingly, at 24 h post-ECS a strong significant pro-
moter methylation was observed compared to sham controls while
a slight tendency toward an increase was observed at 1 h post-ECS.
The Arc promoter was not heavily methylated in sham rats showing
only about 22% methylated clones whereas methylation reached
more than 51% methylated clones at 24 h post ECS (Fig. 2B). The
distribution of the methylation on the individual CpG sites in the
analyzed promoter sequence is depicted in Fig. 2C. The bisulfite
conversion efficiency was calculated based on conversion rates of
non-CpG cytosines and was higher than 98% for both genes.
3.3. Raising novel antiserum against recombinant Arc
To  confirm that the epigenetic modifications did not only influ-
ence gene transcription but also expression of the proteins we
decided to investigate spatiotemporal changes in hippocampal Arc
and c-Fos protein.
Firstly,  the novel antiserum raised against recombinant Arc was
characterized. When applying antiserum from rabbits immunized
with recombinant Arc protein to Western blotting procedures,
the selected antiserum stained a single band of approximately
55 kDa in a protein lysate of hippocampal crude synaptic vesi-
cles (Fig. 3A). The same antiserum recognized a single band with
similar molecular weight in PC12 cells and the band density
increased following incubation with NGF (Fig. 3B), Also, hippocam-
pus extracts from animals treated with ECS contained high levels of
Arc-immunoreactivity compared to sham as revealed by Western
blots (Fig. 3B). Pre-absorption with the immunizing recombinant
protein completely blocked the immunoreactivity (Fig. 3B).
3.4.  The temporal profiles of Arc and c-Fos gene expression after
ECS
Under  sham conditions, only the granular layer of the dentate
gyrus contained single Arc-expressing cells, while no immunore-
activity could be detected in the molecular layer, hilus, stratum
lacunosum-moleculare, and stratum radiatum. Staining of sections
from animals exposed to ECS revealed a strong immunoreaction
in the dentate granule cells at both 1 and 4 h after the stimulation
and a lower level of staining was observed 8 h after the stimulation
(Fig. 4; left panel). No difference from sham was observed 10 min
after ECS. There were no positive cells detected in the dentate gyrus
under sham conditions (24 h). In comparison, ECS-induced c-Fos
protein expression followed a different time course as the stimu-
latory effect on c-Fos expression peaked at 1 h post-ECS, gradually
declining at 4 h and returning to basal levels at 8 h (Fig. 4; right
panel).
The robust staining intensity in hippocampal sections was
observed after both immunohistochemistry (Fig. 4) and in situ
hybridization (Sup. Fig. 1). The time profile in Arc mRNA levels
was comparable to the protein profile with expression in the gran-
ule cell layer seen up to 4 h after the strong stimulus (Fig. 4; left
panel and Sup. Fig. 1). Similarly, the expression of c-Fos mRNA
peaked at 1 h and declined to sham levels at 4 h (Sup. Fig. 1). As
reported earlier (Link et al., 1995), Arc mRNA was detected not only
over the soma of the granule cell layers, but also in the molecu-
lar layer reflecting the translocation to the dendrites of these cells
(Sup. Fig. 1).
3.5.  Differences in neuronal expression of Arc and c-Fos
While acute ECS did not induce Arc expression in the hilus at any
time point, protein expression of c-Fos in the hilus was observed
4 h post-ECS (Fig. 4). The temporal profiles of expression were only
analyzed over the dentate granular layer, where the two  markers
are strongly induced. Notably, in the same hilar cells c-Fos but not
Arc was expressed. Another difference was that the time profile
in Arc revealed the strongest labeling was  seen after 4 h, where
the expression in the granular layer was  highly reduced (Fig. 4).
The same delay was detected in mRNA expression with some
neurons highly expressing c-Fos mRNA in the hilus 4 h after ECS
(Sup. Fig. 1).
4.  Discussion
In  this study, we  explored epigenetic regulation, mRNA expres-
sion and localization of protein products of Arc and c-Fos in the
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Fig. 1. Regulation of H4Ac at the c-Fos (A) and Arc (B) promoter after acute ECS as compared to sham animals. Data are expressed as mean ± SEM relative to Beta-actin, a gene
not  regulated by ECS n = 6/group; p < 0.05, unpaired t-test.
hippocampus of rats treated with acute ECS. We  used ChIP assay-
ing and bisulfite conversion of DNA to show that acetylation of
histone H4 occurs during increased expression of the c-Fos gene,
whereas DNA methylation is strongly induced on the Arc promoter
24 h post-ECS.
A  number of reports have shown that Arc mRNA is rapidly
induced in the dentate granule cells after ECS (Donai et al., 2003;
Fujimoto et al., 2004; Guzowski et al., 1999; Larsen et al., 2005;
Lyford  et al., 1995; Steward and Worley, 2001). Arc mRNA expres-
sion signifies targeting of mRNA to dendritic localization in the
granule cells of the dentate gyrus, where it is translated into pro-
tein (Tzingounis and Nicoll, 2006). The very strong inductions of
Arc after ECS may  have important consequences to hippocampal
function. Thus Arc binds to endophilin 3 and dynamin and this pro-
cess leads to internalization of AMPA receptors (Chowdhury et al.,
2006; Rial Verde et al., 2006). However, the concentration of Arc in
Fig. 2. DNA methylation of the Arc promoter. (A) Sequence of Arc promoter with each CpG numbered and marked bold. (B) Mean ± SEM percentage of cloned Arc promoter
sequences  revealing one or more methylated CpG sites. (C) Mean ± SEM percentage of methylation for each CpG dinucleotide within the Arc promoter. 10 clones per sample,
with  n = 6/group; **p < 0.01, one-way ANOVA with Newman Keul’s post hoc test.
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Fig. 3. Characterization of the polyclonal antiserum raised in rabbit against the recombinant murine Arc protein domain (1–396). The antiserum recognizes a single band of
approximately  55 kDa in enriched synaptic vesicles from rat hippocampus (panel A). Both treatments produce a strong induction of Arc. Detection of Arc immunoreactivity
in  PC12 cells stimulated with NGF or hippocampal protein lysates from rats exposed to either acute ECS or sham treatment reveal a single band of the same size (panel B).
Pre-incubation  with the recombinant Arc completely abolished immunoreactivity (panel B).
the dendrite is probably critical for optimal memory storage. Lack
of Arc function, as revealed by Arc knockout mice, leads to severe
problems in memory consolidation (Plath et al., 2006) and over-
accumulation is seen in patients with severe cognitive impairments
(Greer et al., 2010). In this perspective, the very large accumulation
of Arc in the dendrites and other compartments of neurons seen up
to 4 h after ECS as well as a transcriptional repression resulting from
DNA methylation could impair memory consolidation and lead to
memory loss, which are major early negative side effects after ECT
(Semkovska and McLoughlin, 2010).
Here we show for the first time, that very strong transcriptional
up-regulation of Arc is followed by promoter DNA methylation 24 h
after acute ECS. This may  lead to a transient downregulation of Arc
mRNA and protein expression. At 1 h post-ECS we also observed a
small non-significant increase in DNA methylation. We  used whole
hippocampi for DNA methylation analysis and hence the increase
may be explained by differences in the temporal profile of Arc gene
expression in different subregions of the hippocampus. Maximal
induction of Arc mRNA levels are seen in dentate granule cells
4 h after the stimulus whereas in the CA1 and parietal cortex the
expression peaks within 1 h and returns to baseline levels within 2 h
(Larsen et al., 2005). This indicates that gene expression and pos-
sibly DNA methylation patterns have different temporal profiles
depending on the subregion.
This  is not the first study to report changes in DNA methylation
following ECS. A genome-wide study revealed that approximately
1.4% of 219,991 CpGs measured showed rapid active demethyla-
tion or de novo methylation in dentate granule neurons following
ECS (Guo et al., 2011). A number of recent studies have highlighted
the importance of DNA methylation in synaptic plasticity. A con-
textual fear conditioning study revealed very dynamic changes in
hippocampal DNA methylation of the promoters of two  genes, Pp1
and Reelin (Miller and Sweatt, 2007). In another study it was  found
that Reelin and Bdnf exhibited rapid and dramatic changes in cyto-
sine methylation when DNMT activity was inhibited (Levenson
et al., 2006). Furthermore, double knockout of Dnmt1 and Dnmt3a
results in abnormal long-term plasticity in the hippocampal CA1
region together with deficits in learning and memory (Feng et al.,
2010)
We also examined H4Ac association with the promoters of Arc
and c-Fos. We  found a significant increase of histone acetylation
at 1 h post-ECS at the c-Fos but not Arc promoter. An increase
in H4Ac at the promoter of c-Fos has previously been reported
30 min  and 2 h after acute ECS (Tsankova et al., 2004). Further-
more, it has recently been shown that spatial memory deficits
induced by ECS could be reduced by pre-treatment with the HDAC
inhibitor phenylbutyric acid (PBA) (Yao et al., 2010). It was found
that acute ECS decreased expression of c-Fos, but not Arc, at 24 h
post  ECS. Pre-treatment with PBA prevented the decrease in c-Fos
expression emphasizing that H4Ac is likely involved in transcrip-
tional regulation of c-Fos. In addition, it should be considered that
HDAC inhibition has been found to reduce global DNA methyla-
tion, DNMT1 protein levels, and its interactions with chromatin
(Arzenani et al., 2011).
To  further characterize expression of hippocampal Arc and c-Fos
we carried out a detailed analysis of their spatiotemporal profiles
of expression. Arc mRNA levels reached a plateau at 1–4 h, while
c-Fos mRNA levels peaked significantly earlier at 1 h post-ECS. This
is also reflected by the observation that the intensity of Arc and
c-Fos immunostaining peaked in the dentate granular at 4 h and
1 h, respectively. Furthermore, 8 h after the stimulation Arc protein
remained elevated whereas c-Fos protein was not detected. The
strong induction of both genes in the dentate granule cells sug-
gests that they are induced through the same or partly overlapping
signaling pathways. However, despite the shared increase in mRNA
abundance after ECS the composition of transcription factors medi-
ating the activation of the two genes is likely different. It has been
shown that Arc is induced by MEK-dependent pathways (Waltereit
et al., 2001; Yasuda et al., 2007). Also, the BDNF-induced increase
of Arc mRNA is rapidly mediated by MEK, whereas the long-term
changes are Ca2+-dependent (Yasuda et al., 2007).
We also investigated Arc-immunoreactivity that was found
present throughout the neuronal cytoplasm and in the nucleus of
sham animals. A strong accumulation of Arc-immunoreactivity was
also observed in the nuclei of neurons after ECS. The morphological
data suggest that Arc is transported into the nucleus, but the possi-
ble functional significance of Arc in the nucleus is unknown. It is of
interest that neurons found to contain cytoplasmic and nuclear Arc
were virtually absent 24 h after ECS, suggesting that also Arc located
in other intracellular compartments than the dendrites is regulated
by neuronal activity. The precise localization of the two  gene prod-
ucts revealed that with one exception they were expressed in the
same hippocampal structures. It has been shown that only a maxi-
mum of 5% of the neurons containing Arc after ECS are GABAergic,
the vast majority are glutamatergic (Vazdarjanova et al., 2006).
However, we  find that a population of hilar neurons that are likely
inhibitory express c-Fos and not Arc. The time course study revealed
that these neurons are not only different in their content of IEGs but
also display a slower reduction of c-Fos expression upon acute ECS
than the dentate granule cells. The activated neurons are interneu-
rons many of which contain neuropeptide Y (NPY) (Woldbye et al.,
1996). NPYergic interneurons are likely involved in inhibition of
excitation in the granule cells (Madsen et al., 1999; Woldbye et al.,
1997). This raises interesting perspectives about differences in the
regulation of gene expression in hilar interneurons and granule
cells.
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Fig. 4. Comparison of Arc and c-Fos protein expression in the granular cell layer of
the same animals after a single ECS. ECS-induced Arc and c-Fos protein expression
displays  spatiotemporal differences, because whereas acute ECS triggers massive
protein expression of both Arc and c-Fos expression in the granula layer of the
dentate  gyrus, the stimulated expression of Arc declines at a lower rate than c-
Fos. Note that ECS triggers expression of c-Fos while leaving Arc expression almost
undetectable in the hilus.
The results of this study will contribute to a better under-
standing of the molecular mechanisms governing gene expression
after ECS. DNA methylation is particularly interesting as it might
explain memory deficits experienced by patients after ECT. How-
ever, further studies are needed to reveal the mechanisms by
which Arc becomes methylated. This should involve signaling
pathways and catalyzing proteins such as the DNMTs. In addi-
tion, other memory-related genes including N-methyl-d-aspartate
receptor 2A/B (Grin2A/2B), postsynaptic density 95 (Psd95), and
Creb are obvious candidates for investigation of DNA methylation. A
comprehensive understanding of the molecular mechanisms
induced by ECS may  enable pharmaceutical relieving of side effects
and ultimately development of novel pharmaceuticals mimicking
the positive effects of ECT.
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Electroconvulsive therapy (ECT) remains one of the most effective treatments of major depression. It has been
suggested that the mechanisms of action involve gene expression. In recent decades there have been several
investigations of gene expression following both acute and chronic electroconvulsive stimulation (ECS). These
studies have focused on several distinct gene targets but have generally included only few time points after
ECS for measuring gene expression. Here we measured gene expression of three types of genes: Immediate
early genes, synaptic proteins, and neuropeptides at six time points following an acute ECS. We ﬁnd signiﬁcant
increases for c-Fos, Egr1, Neuritin 1 (Nrn 1), Bdnf, Snap29, Synaptotagmin III (Syt 3), Synapsin I (Syn 1), and
Psd95 at differing time points after ECS. For some genes these changes are prolonged whereas for others they
are transient. Npy expression signiﬁcantly increases whereas the gene expression of its receptors Npy1r, Npy2r,
and Npy5r initially decreases. These decreases are followed by a signiﬁcant increase for Npy2r, suggesting
anticonvulsive adaptations following seizures. In summary, we ﬁnd distinct changes in mRNA quantities that
are characteristic for each gene. Considering the observed transitory and inverse changes in expression patterns,
these data underline the importance of conducting measurements at several time points post-ECS.
© 2014 Elsevier B.V. All rights reserved.
1. Introduction
Despite many years of research, electroconvulsive therapy (ECT) is
still the most effective treatment for major depression. The clinical efﬁ-
cacy ranges from 85 to 90%, whereas for pharmaceutical antidepres-
sants it is only 60–65% (Schloss and Henn, 2004). The majority of
patients undergoing ECT has previously been administered at least
one antidepressant without success, further emphasizing the efﬁcacy
of the treatment (Moksnes and Ilner, 2010). ECT requires repeated ad-
ministration for clinical efﬁcacy but has a faster onset than antidepres-
sant therapy (Pagnin et al., 2004). The ﬁrst signs of improvements can
often be observed after the ﬁrst ECT and occurs in 65% of patients
(Moksnes and Ilner, 2010). Unfortunately, adverse effects such as cogni-
tive and memory deﬁcits have been reported after ECT, making it the
last choice of treatment (Fava and Kendler, 2000).
Formany years, research has been focused on elucidating the antide-
pressant mechanisms of ECT. Electroconvulsive stimulation (ECS), an
animal model of ECT, causes a widespread release of neurotransmitters,
which affects a variety of transporters and receptors in the brain
(Schloss and Henn, 2004). The therapeutic mechanism likely involves
cellular changes, including increased neurogenesis, increased cell prolif-
eration, ﬁber sprouting, and enhanced synaptic signaling all of which
have been observed after ECS (Schloss and Henn, 2004). Such changes
have been suggested to be orchestrated at the level of gene expression
and the ﬁrst studies of ECS-induced gene expression were published
decades ago (Leviel et al., 1990; Winston et al., 1990; Xie et al., 1989;
Zawia and Bondy, 1990). Further studies have revealed regulation of
distinct neurotrophic signaling pathways (Altar et al., 2004), synaptic
vesicle proteins (Elfving et al., 2008; Yamada et al., 2002), and immedi-
ate early genes (IEGs) (Dyrvig et al., 2012; Tsankova et al., 2004).
IEGs are rapidly induced by extracellular stimuli and act as tran-
scription factors on downstream targets or as effector proteins. FBJ
osteosarcoma oncogene (c-Fos) and early growth response 1 (EGR1)
upregulation leads to long-term adaptions in neuronal gene regulation
and may affect synaptic plasticity (Abraham et al., 1994; Kaczmarek,
1992). NRN 1 is an activity-dependent protein involved in neuronal
plasticity by promoting neuronal migration (Naeve et al., 1997). These
IEGs have all previously been found to be increased in the hippocampal
formation following ECS (Newton et al., 2003; O'Donovan et al., 1998;
Woldbye et al., 1996). Neuropeptides have received particular interest
as part of the neurotrophic hypothesis of depression. Brain-derived
neurotrophic factor (Bdnf) has been the leading candidate as acute
and chronic stress decreases its expression whereas antidepressants
have the opposite effect (Berton and Nestler, 2006). Neuropeptides
are of particular interest due to their neuroprotective effects. BDNF acti-
vates TrkB inﬂuencing its associated pathways that have been
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implicated in neuronal differentiation, neurite outgrowth, cell survival,
and synaptic plasticity (Boulle et al., 2012). Neuropeptide Y (NPY) has
been found to inhibit seizures and has been linked to anxiety and de-
pression (Kask et al., 2002; Thorsell et al., 2000; Vezzani et al., 1999;
Woldbye et al., 1997). In the brain, NPY primarily bind neuropeptide Y
receptor Y1 (NPY1R), neuropeptide Y receptor Y2 (NPY2R), and neuro-
peptide Y receptor Y5 (NPY5R) and exerts inhibitory effects on neuronal
hyperexcitability in hippocampal seizure models (Vezzani et al., 1999;
Woldbye and Kokaia, 2004). In the hippocampus, NPY2R plays a role
in the seizure suppressing properties whereas NPY1R may facilitate
seizures (Bahh et al., 2005; Lin et al., 2006a).
The widespread release of neurotransmitters following ECS affects
both transporters and receptors (Schloss and Henn, 2004). Synaptic
vesicle proteins are required for vesicle fusion and neurotransmitter re-
lease. Expression of synaptosomal-associated protein, 29 kDa (Snap29),
Syt 3, and Syn 1 was recently investigated in the hippocampus after
acute and chronic ECS and regulation of such genes has been suggested
to be a part of the therapeutic response (Elfving et al., 2008). Postsynap-
tic density protein 95 (PSD95) is a scaffold protein that maintains
normal function of the NMDA receptor (Lin et al., 2006b) and PSD95
protein levels are reduced after ECS (Yao et al., 2010). Such reduction
may impair learning and memory (Sultana et al., 2010).
The genes selected for the present study have previously been found
to be regulated at the expression and/or protein level. Most of these
studies have investigated changes in expression level only at one or
two timepoints. However, the genes that have been investigated belong
to diverse functional classes and expression changes may be short
lasting or prolonged due to direct regulation via transcription factors
or epigeneticmodiﬁcations. Thus, itmay be important to include several
time points to make correct conclusions. To test this hypothesis, we
decided to investigate the temporal gene expression proﬁle up to 48 h
following an acute ECS. To our knowledge this is the ﬁrst study present-
ing the expression of several gene classes at numerous time points
following an acute ECS. We decided to focus on the hippocampus due
to its recognized role in depression and because gene expression is
heavily affected by ECS in this region (Altar et al., 2004).
2. Materials and methods
2.1. Animals and treatment
Adult male Sprague–Dawley rats (270–350 g, Charles River Labo-
ratories, Hamburg, Germany) were used. All experiments were con-
ducted in accordance with guidelines of the National Institute of
Health (NIH Publications No. 85-23, 1985) and the Animal Experimen-
tation Inspectorate, Ministry of Justice, Denmark. Rats received a single
transauricular ECS using a metal forceps (50 mA, 0.5 s, unidirectional
square wave pulses) as previously described (Woldbye et al., 1996).
All animals developed tonic-clonic seizure activity lasting 20–30 s.
Animals were sacriﬁced 1 h, 4 h, 8 h, 16 h, 24 h or 48 h after ECS.
Sham animals were handled similarly but without the passing of
current. Three sham animals were sacriﬁced after 1 h and three animals
after 24 h. After decapitation, the hippocampi were quickly removed,
dissected and frozen in liquid nitrogen. The samples were stored at
−80 °C until use.
2.2. Tissue homogenization and RNA extraction
Total RNAwas extractedwith anAllPrep DNA/RNAMini Kit (Qiagen,
Germany), followingmanufacturer's instructions for simultaneous puri-
ﬁcation of genomic DNA and total RNA from Animal Tissues. The tissue
was disrupted and homogenized for 30 s. with a T10 basic ULTRA
TURRAX Homogenizer (IKA, Germany). The RNA was stored at
−80 °C until further use.
2.3. RNA quality assessment and cDNA synthesis
RNA purity and concentration were determined with a Nano-
Photometer™ (IMPLEN, Germany). All samples were gel electrophorized
on a 1.2% agarose gel stainedwith ethidium bromide to ensure integrity
of the RNA. All samples displayed sharp 18 s and 28 s rRNA bands. To
prevent DNA carryover, 1 μg of RNA was DNase digested with DNase I
(Thermo Scientiﬁc, Germany), according to manufacturer's instruc-
tions. 100 ng of RNAwas reverse transcribedwith a RevertAid™ Premi-
um First Strand cDNA Synthesis Kit (Thermo Scientiﬁc, Germany),
using the protocol for RT-qPCR. No reverse transcriptase control reac-
tions were prepared identically but without addition of Revertaid Pre-
mium Enzyme Mix. The reactions were incubated at 25 °C for 10 min,
50 °C for 20 min, 65 °C for 10 min, and 85 °C for 5 min. cDNA and no re-
verse transcriptase reactionswere diluted 1:40withDEPCwater andused
directly as qPCR template.
2.4. Real-time PCR
The real-time PCR reactions were performed in a Mx3000P Real-
Time PCR System (Stratagene, USA), using 96-well PCR plates sealed
with heat seal ﬁlm. The reaction mixtures consisted of 1× Maxima
SYBR Green qPCR Master Mix (2×), ROX solution provided (Thermo
Scientiﬁc, Germany) with a ﬁnal ROX concentration of 10 nM, 0.5 μM
of each primer, and 10 μl diluted cDNA in a total volume of 20 μl. The
cycling protocol started with one cycle of 95 °C for 10 min for enzyme
activation, followed by 40 cycles of: 95 °C for 30 s., 60 °C for 30 s, and
72 °C for 30 s. All samples were run in duplex and reactions were
repeated if any deviation was observed. After ﬁnished ampliﬁcation, a
melting curve program was performed starting at 60 °C and ending at
95 °C to investigate for presence of primer-dimers or non-speciﬁc
amplicons.
Eight housekeeping genes have previously been tested in hippocam-
pal tissue following ECS (Fryland et al., 2012). UsingNormﬁnder software
it was found that Actb and CycA were the best-suited combination of
reference genes for normalization. CycA primers have been published
previously (Peinnequin et al., 2004) and used in several publications.
Sequences for the remaining transcripts were obtained from NCBI
(http://www.ncbi.nlm.nih.gov/gene/) and primers were designed
using Primer-BLAST (http://www.ncbi.nlm.nih.gov/tools/primer-blast/).
The primers were designed to have amplicon sizes of 100–150 bp and
to be intron spanning whenever possible (see Table 1 for primer
sequences). PCR products were gel electrophorized on a 2% agarose
gel stained with ethidium bromide to test for the presence of a speciﬁc
band of the correct size. Standard curves were generated for each prim-
er pair to determine efﬁciencies and all were in the range of 90–110%.
Gene expression was calculated using the efﬁciency corrected method
of Pfafﬂ (2001). For each animal gene expression was normalized
using the geometric mean of Actb and CycA. Target gene expression in
ECS groups was compared to expression in SHAM animals decapitated
after 1 h and 24 h. No statistically signiﬁcant differences in target
gene expressionwere observed between these SHAMgroups (unpaired
t-test) except for EGR1 (13% difference). Statistical data analysis was
performedusing one-wayANOVAwithDunnett's post hoc test. All anal-
yses were conducted using GraphPad Prism 5.0 (GraphPad software,
San Diego, CA, USA). p values b 0.05 were considered to be statistically
signiﬁcant.
3. Results
3.1. Immediate early genes
IEGs c-Fos, Egr1 and Nrn 1 have previously been found to be highly
upregulated after ECS and this is also evident in this study (Fig. 1).
For c-Fos we observe a more than 20-fold increase at 1 h post-ECS
(p b 0.001) after which the expression gradually declines (Fig. 1a). At
9M. Dyrvig et al. / Gene 539 (2014) 8–14
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4 h, the expression is still more than 2-fold increased compared to sham
but thereafter the expression continues to drop, reaching59% compared
to sham. Similar to c-Fos, the expression of Egr1 is dramatically
increased at 1 h post-ECS with a near 5-fold increase as compared to
sham (p b 0.001; Fig. 1b). Expression then quickly declines and remains
at levels comparable to sham for the remaining time points. The ex-
pression of Nrn 1 (Fig. 1c) increases more slowly after ECS as compared
to c-Fos and Egr1. A minor 12% increase is observed at 1 h after which
expression reaches amaximum 75% increase at 4 h (p b 0.001). Expres-
sion then starts to drop but remains signiﬁcant with a 44% increase
above sham at 8 h (p b 0.001). At later time points, expression returns
to sham levels. Bdnf expression (Fig. 1d) is also included here, as the
gene has several promoters, some of which can be induced as an IEG
(Lauterborn et al., 1996). At 1 h and 4 h post-ECS, the expression of
Bdnf increases signiﬁcantly approximately 3.4-fold compared to sham
(p b 0.001). At 8 h the Bdnf expression decreases but remains 55%
Table 1
Characteristics of gene-speciﬁc qPCR primers.
Gene name Accession no. Primer sequence Amplicon size (bp) Spanning Intron
Actb NM_031144.3 (+) CCTCTGAACCCTAAGGCCAACCGTGAA 123 +
(−) AGTGGTACGACCAGAGGCATACAGGG
Cyca NM_017101.1 (+) TATCTGCACTGCCAAGACTGAGTG 127 −
(−) CTTCTTGCTGGTCTTGCCATTCC
c-Fos NM_022197.2 (+) GGTCACAGAGCTGGAGCCCCTGTGC 150 −
(−) TCGTTGCTGCTGCTGCCCTTTCGGT
Egr1 NM_012551.2 (+) CAACCCTACGAGCACCTGACCACAG 137 +
(−) TCCAGGGAGAAGCGGCCAGTATAGG
Nrn 1 NM_053346.1 (+) AGGTCTGCGGTCGCAAATGGTTTGA 141 +
(−) AAAGACTGCATCGCACTTGCCTGCT
Bdnf (exon IX) NM_001270638.1 (+) AGTCCCGGTATCAAAAGGCCAACTGAA 147 −
(−) AGGGCCCGAACATACGATTGGGTAGT
Npy NM_012614.2 (+) CATGGCCAGATACTACTCCGCTCTGCGA 141 +
(−) AGCCTTGTTCTGGGGGCATTTTCTGTGC
Npy1r NM_001113357.1 (+) TGGTGCTGCAGTATTTTGGCCCACT 150 +
(−) GCAGCATGACGTTGATTCGTTTGGTCT
Npy2r NM_023968.1 (+) TGTTCCATCATCTTGCTGGGCGTAGT 153 −
(−) AAGAGTGAATGGCAGGCACAGGGTG
Npy5r NM_012869.1 (+) ACGGCAAACCATGGCTACTTCC 121 −
(−) GCAGTGCTGAGCCAAAGGTCT
Snap29 NM_053810.3 (+) CCTCCACCTGAGCAGAATGGCA 107 +
(−) GGGTGGCTGGCTTGGTACTTG
Synapto-tagmin III NM_019122.1 (+) TCCTGCTGCCTCCTAGTGGTG 137 +
(−) TGGGTCTGCTTGGGTGGTCA
Syn 1 NM_001110782.2/NM_019133.2 (+) GTCATCGACGAGCCGCACAC 139 +
(−) CCACGGAGAATCCACCATTGGC
Psd95 NM_019621.1 (+) AGCTTCCGCTTCGGGGATGT 148 +
(−) ACCTTGACCACTCTCGTCGCT
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Fig. 1. Expression of immediate early genes following acute ECS. mRNA expression in the hippocampus of sham rats or rats exposed to acute ECS at: 1 h, 4 h, 8 h, 16 h, 24 h, and
48 h (n= 6/group). c-Fos (a), Egr1 (b),Nrn 1 (c), and Bdnf (d). Data are presented asmean value of the groupwith SEM. *p b 0.05, ***p b 0.001, one-way ANOVAwith Dunnett's post-hoc test.
10 M. Dyrvig et al. / Gene 539 (2014) 8–14
 124 
higher than sham (p b 0.05). Thereafter expression decreases to sham
levels for the remaining time points.
3.2. Npy system
At the ﬁrst hours following an acute ECS, Npy expression (Fig. 2a)
does not change signiﬁcantly. At 4 h we observe a small increase after
which expression increases signiﬁcantly 3.3-fold compared to sham at
8 h (p b 0.001) and remains at 2.7-fold at 16 h (p b 0.001). The expres-
sion then declines to sham levels at 24 h and 48 h. The expression ofNpy
receptors initially declines for all investigated subtypes (Figs. 2b–d):
Npy1r is at 45% (p b 0.001), Npy2r at 78% (p b 0.05), and Npy5r at 58%
(p b 0.001) compared to sham after 4 h. The expression of Npy1r
then increases but remains signiﬁcantly decreased at 8 h (p b 0.01),
16 h (p b 0.001), and 24 h (p b 0.05) compared to sham. At 48 h the
expression is near sham levels. The expression of Npy2r continues to
decrease and reaches 63% of shamat 8 h (pb 0.001). Expression then in-
creases signiﬁcantly, being 23% higher than sham at 48 h (p b 0.05).
After an initial decrease at 1 h and 4 h, the expression ofNpy5r increases
to near sham levels at 8 h and 16 h. At 24 h expression is signiﬁcantly
decreased (p b 0.05) before returning to sham levels at 48 h.
3.3. Synaptic proteins
As opposed to the expression changes observed for IEGs and theNpy
systemonly small, though signiﬁcant, changes are observed for synaptic
proteins. Snap29 (Fig. 3a) reaches amaximal 17% increase in expression
at 8 h (p b 0.001). Expression remains elevated at 16 h (p b 0.01) and
then gradually declines to sham levels. Syt 3 (Fig. 3b) remains stable
for the ﬁrst period following ECS and then signiﬁcantly increases at 16
h (p b 0.01) by 12% compared to sham. A similar level is observable at
24 h though not statistically signiﬁcant before expression declines at
48 h. The expression of Syn 1 (Fig. 3c) follows a different pattern with a
gradual increase after ECS, which reaches signiﬁcance at 4 h (p b 0.05).
Expression further increases at 8 h (p b 0.001) and reaches a maximum
37% increase at 16 h (p b 0.001). Expression then starts decreasing but is
still signiﬁcantly increased at 24 h (p b 0.05), before returning to sham
levels at 48 h. The expression of Psd95 (Fig. 3d) does not initially increase
following ECS but gradually increases after 4 h (p b 0.01) and reaches a
maximum 21–23% increase at 8 h and 16 h (p b 0.001). Expression
then declines but remains signiﬁcantly increased with 16% at 24 h
(p b 0.001) and 14% at 48 h (p b 0.01) as compared to sham.
4. Discussion
Here we investigate the temporal gene expression proﬁle of several
genes in the hippocampus following an acute ECS. We observe that
changes in gene expression following an acute ECS are often relatively
transient. c-Fos, Egr1, and Syt 3 are signiﬁcantly regulated only at a single
of our selected time points. Thus, selecting only one time point for
measurements may be clearly insufﬁcient. As seen with Npy2rmRNA
measurements, gene expression may even follow an inverse pattern
leading to spurious conclusions if only time points immediately post-
ECS are selected. This observation may explain why the data presented
here both augments and show disagreements with other studies. For
instance, Elfving et al. (2008) previously investigated the expression
of synaptic vesicle proteins in the hippocampus and frontal cortex 6 h
after acute and chronic ECS. In their study Snap29 expression was
found to be signiﬁcantly increased and we conﬁrm that expression is
signiﬁcantly upregulated at 8–16 h after an acute ECS. For Syn 1 they
found a non-signiﬁcant upregulation whereas we ﬁnd a signiﬁcant up-
regulation 4–24 h after ECS. They also found Syt 3 to be signiﬁcantly
downregulated which is in contrast to a signiﬁcant upregulation at 16
h in the present study. At 4 hwe do in fact observe a non-signiﬁcant de-
crease for Syt 3which emphasizes the likeliness of decreased expression
at 6 h as they observe. Elfving et al. (2008) suggest that Snap29 upregu-
lation and Syt 3 downregulation may be early speciﬁc markers for the
effect of ECS. However, our data emphasize that the expression changes
are transient and that a single time point is not enough to make conclu-
sions regarding therapeutic mechanisms.
In the clinical setting, ECT is administered repeatedly to achieve a
full therapeutic effect (Pagnin et al., 2004). However, in many patients
the ﬁrst improvements can be observed already after the ﬁrst ECT
(Moksnes and Ilner, 2010) which suggests involvement of both acute
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Fig. 2. Expression of Npy and Npy receptor genes following acute ECS. mRNA expression in the hippocampus of sham rats or rats exposed to acute ECS at: 1 h, 4 h, 8 h, 16 h, 24 h,
and 48 h (n= 6/group). Npy (a), Npy1r (b), Npy2r (c), and Npy5r (d). Data are presented asmean value of the group with SEM. *p b 0.05, **p b 0.01, ***p b 0.001, one-way ANOVAwith
Dunnett's post-hoc test.
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mechanisms and long-term adaptions. As evident in the current study,
expression of distinct gene classes is affected differently and exhibits
various delays before transcription is affected. As expected, IEGs are af-
fected rapidly. c-Fos and EGR1 function as transcription factors and like-
ly induce regulation of downstream targets. The transient increases in c-
Fos, Egr1, and Nrn 1 expression is consistent with previous ﬁndings
(Newton et al., 2003; Wallace et al., 1998; Zawia and Bondy, 1990).
Similar to the apparent decrease in c-Fos expression at 24 h and 48 h,
a decrease has also been observed 24 h after chronic ECS (Tsankova
et al., 2004; Winston et al., 1990). More recently Calais et al. (2013) in-
vestigated the expression of IEGs c-Fos, Egr1 and Arc after acute and
chronic ECS in the hippocampus for up to 90 days after the last seizure.
As observed in the current study, acute ECS induced a transient increase
in expression of c-Fos and Egr1 after which a signiﬁcant decrease was
observed. The induction of IEGs is signiﬁcantly lower in animals that
receive chronic ECS as compared to animals receiving only one shock
(Calais et al., 2013; Jung et al., 1996) and it has been found that chronic
treatment desensitizes subsequent ECS-induced IEG expression
(Tzingounis and Nicoll, 2006; Winston et al., 1990). Thus, IEGs are not
likely to be related to the antidepressant properties of chronic ECS
(Larsen et al., 2005). However, as observed here, IEGs may be involved
in an immediate acute response that leads to gene regulation of down-
stream targets (Fig. 4).
In the current study, gene expression is presented relative to SHAM
animals sacriﬁced after 1 h and 24 h. At these time pointswe observe no
or very limited differences between the SHAM animals. However, as we
measure gene expression at several time points after ECS it should be
noted that expression of some genes involved in synaptic plasticity
and memory formation are affected by circadian ﬂuctuations in the rat
hippocampus (Eckel-Mahan, 2012). To our knowledge such observa-
tions has only beenmade for BDNF and c-Fos. Using in situ hybridization
it was found that BDNF show up to 20% of circadian ﬂuctuations (Schaaf
et al., 2000). In dentate gyrus the levels peak during the inactive period
and are decreased at the start of the active period. In CA3, a minor in-
crease is observed during the active period. As these changes are partly
opposing and we use whole hippocampus, circadian inﬂuences should
be limited. For c-Fos it was found that expression gradually increases
to an approximate 3-fold increase when animals are active during the
dark-cycle (Grassi-Zucconi et al., 1993). This could potentially affect
the measurement after 16 h, the only performed during the dark-
cycle. However, we do not observe that expression is increased at this
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Fig. 3. Expression of genes coding for synaptic proteins following acute ECS. mRNA expression in the hippocampus of sham rats or rats exposed to acute ECS at: 1 h, 4 h, 8 h, 16 h, 24 h, and
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Dunnett's post-hoc test.
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Fig. 4.Diagram showing proposed sequence of events based on the presented data and the
literature. Dashed line depicts gene not included in the analysis in this article.
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time point. This may be explained by the fact that c-Fos expression is
blocked for a prolonged period after ECS (Winston et al., 1990).
Bdnf has a complex structure with eight 5′-untranslated exons
and oneprotein coding 3′-exon (Aid et al., 2007). Activity dependent in-
creases in Bdnf expression has been reported to occur within 20 min of
stimulation (Gall, 1993; Isackson et al., 1991), which is suggestive of an
IEG response. This was investigated by Lauterborn et al. (1996) who
found that Bdnf exon IV and VI (according to the new nomenclature
(Aid et al., 2007))was transcribed in the presence of the protein synthe-
sis inhibitor cycloheximide. Herewe investigated expression of the total
Bdnf transcript (exon IX). It is apparent that Bdnf expression increases at
1 h as is the case for c-Fos and Egr1. It is also evident that Bdnf expression
remains increased substantially longer than c-Fos and Egr1, which may
be a result of expression driven by non-IEG response promoters. Indeed,
it has been found that Bdnf mRNA is signiﬁcantly increased in the den-
tate gyrus 6 h after an acute ECS, but expression decreases to sham
levels at 24 h, whereas chronic ECS causes signiﬁcant increases up to
48 h post-ECS (Zetterström et al., 1998). Thus, it is likely that IEG re-
sponse promoters primarily drive Bdnf expression induced by acute
ECS, whereas transcription is driven at non-IEG response promoters
after chronic ECS. A similar observation was made for Npy where it
was found that Npy gradually increased with the number of ECS
(Mikkelsen and Woldbye, 2006). Some patients show improvements
after the ﬁrst ECT. However, repeated stimulation delivered consecu-
tively over several days (6–14 days) is required to produce long-term
beneﬁcial effects (Silverstone and Silverstone, 2004). Genes such as
Bdnf and Npy that we ﬁnd to be highly expressed after an acute ECS,
and gradually increase or remain expressed for prolonged periods after
chronic ECS, could offer an explanation for these clinical observations.
However, it should benoted that ECT-induced gene expression differ be-
tween regions and these changes may even cause opposing behavioral
outcomes depending on the region. The study by Elfving et al. (2008)
support that transcriptional changes differ between brain regions.
Even more importantly, in a study by Taliaz et al. (2013) it was found
that differences in the expression of BDNF in the hippocampus and ven-
tral tegmental area causes opposite outcomes. It was found that chronic
ECS induced BDNF upregulation in the hippocampus and downregula-
tion in the ventral tegmental area. An antidepressant like-effect was
not prevented by blocking hippocampal BDNF induction in the hippo-
campus but achievedbyBDNFknockdown in the ventral tegmental area.
The Npy system is regulated after both ECS and seizures (Husum
et al., 1998; Mikkelsen et al., 1994). The antidepressant properties of
NPY have been suggested to involve anticonvulsive adaptions (Sackeim
et al., 1983). However, the anticonvulsant and anxiolytic effects of NPY
likely involve activation of different receptors and take place in distinct
brain regions, namely the hippocampus and amygdala (Mikkelsen and
Woldbye, 2006). Expression of Npy1r, Npy2r (Madsen et al., 2000), and
Npy5r (Christensen et al., 2006) are affected by ECS. Here we ﬁnd that
Npy2r is signiﬁcantly upregulated 48 h after an acute ECS. Considering
the anticonvulsive properties of NPY2R in the hippocampus this corre-
sponds well with the fact that seizure thresholds increases as ECT
treatment regimen advances (Post et al., 1996).
In conclusion, the results of this studywill contribute to an improved
understanding of the temporal gene expression proﬁle after an acute
ECS. The patterns presented highlight the widespread actions of ECS
and the diversity of expression changes for each gene type.More impor-
tantly, this study emphasizes the importance of including several time
points for investigations of ECS-induced gene expression, particularly
when investigating expression immediately following acute ECS. As
this study only investigates transcriptional changes, future experiments
should be performed to investigate how these correlates with protein
expression. We have previously (Dyrvig et al., 2012) measured c-Fos
protein expression 10 min, 1 h, 4 h, 8 h, and 24 h after ECS and for this
gene we observe the expected correlation. However, for the remaining
genes it should be established if minor or inverse transcriptional chang-
es are also evident at the protein level.
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4. DISCUSSION 
The objective of this dissertation has been to study DNA methylation in relation to 
the etiology and treatment of psychiatric disorders. In the presented manuscripts we 
established that DNA methylation is important for transcriptional regulation of 
BRD1 and that the SNP rs138880, located in the BRD1 promoter region, is 
associated with increased methylation. We then established that the CHRNA7 gene 
is regulated by DNA methylation in the adult brain and that HDAC inhibition 
increases its expression and reduces promoter methylation. Finally, we focused on 
methylation changes at the Arc promoter following ECS. Thus, the overall focus of 
the dissertation was on changes in DNA methylation resulting from both 
endogenous (genetic) and exogenous (ECS and treatment) sources.  
4.1. RELEVANCE OF BLOOD AS A BIOMARKER 
It is difficult to study psychiatric diseases as brain tissue can only be obtained post 
mortem or from animal models (Smith et al. 2014). Creating valid animal models of 
neuropsychiatric disorders is extremely challenging both because of the subjective 
nature of symptoms and particularly because of our limited understanding of disease 
mechanisms (Nestler & Hyman 2010). Even if we had better understanding, it would 
be difficult to create a model with good construct validity because of the highly 
complex genetic architecture of psychiatric disorders. The use of post mortem brain 
tissue is informative but it is particularly limited by the capacity to study on-going 
disease stages. Therefore, blood is often used as a biomarker that may reflect 
mechanisms occurring in the brain (Tylee et al. 2013). In study 1 we also use blood, 
but a relevant question is how suitable blood really is as a biomarker for the brain.   
   It is known that DNA methylation patterns show large variations across the 
genome by developmental stage and by tissue type (Liang et al. 2011). However, it 
has been reported that early life adverse environment leaves a long lasting epigenetic 
footprint in DNA methylation that can be observed in both blood and brain (Menke 
& Binder 2014). A review of the epigenomic literature revealed that CpG-island 
methylation levels are highly correlated between blood and brain (Tylee et al. 2013). 
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DNA methylation levels may be affected by environmental insults as mentioned 
above, but also by genetic variations. In a very recent study metQTLs were 
compared across ancestry, developmental stage, and tissue type (Smith et al. 2014) 
and it was found that metQTLs were consistently detected across these groups. 
Comparisons of tissue types included four brain regions (frontal cortex, temporal 
cortex, cerebellum, and pons) and peripheral blood. Comparisons between blood 
samples and brain tissue among individuals of European ancestry revealed an 
overlap of metQTLs of 18.5-31.6%, whereas the overlap between brain regions was 
35.8-71.7%. Thus, there is overlap of detected metQTLs, but the size emphasise that 
additional examinations in relevant tissues are needed to make thorough 
conclusions. In study 1 we observe that methylation of CpG sites cg15145965 and 
cg06057569 in the BRD1 promoter region are correlated with rs138880 alleles in 
both adipose tissue and blood. In addition, promoter constructs carrying the 
rs138880 risk allele (C-allele) causes decreased transcriptional drive in a neuronal 
cell line (Qvist et al., manuscript submitted), which provides evidence that the SNP 
is also relevant in brain tissue.  
 
4.2. RATIONALE FOR STUDYING EPIGENETIC ALTERATIONS 
CAUSED BY GENETIC VARIANTS 
In study 1 we find that the rs138880 SNP located in the BRD1 promoter region is 
associated with increased DNA methylation. Current evidence suggests that DNA 
methylation is a secondary event following decreased promoter activity (Jones 
2012). MatInspector software analysis suggest that the transcriptional repressor 
HES1 binds specifically to the risk C-allele as was reported previously (Severinsen 
et al. 2006) and that BPTF and RBP2 bind specifically to the A-allele. Thus, most 
likely DNA methylation is a consequence of and not the cause of reduced BRD1 
expression.  
   In study 2 we find that DNA methylation at Region 2+3 is significantly correlated 
with CHRNA7 expression in the human temporal cortex. A large number of SNPs in 
the core promoter of CHRNA7 are associated with decreased transcription (Leonard 
et al. 2002). We did not genotype the samples but did metQTL analysis and found 
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that CHRNA7 promoter SNPs rs6494165, rs1514246, and rs883473 showed 
significant correlation with methylation levels of CpG sites located in Region 2 and 
3. This suggests that as for the BRD1 promoter, decreased transcriptional activity of 
the CHRNA7 promoter could increase the chance of de novo methylation and lead to 
higher methylation levels as is observed for two of the biopsies.  
   So what is the importance of linking methylation to reduced BRD1 and CHRNA7 
expression? If it should become a therapeutic goal to normalise BRD1 expression, or 
increase CHRNA7 expression as an adjuvant to potentiate α7 nAChR agonists, there 
are a number of options. 1) Change the genotype of the SNP. 2) Target the 
transcription factor binding to the SNP or increase transcription via other 
transcription factors. 3) Reverse DNA methylation by pharmacological intervention, 
which would leave the region accessible to other transcription factors. Only option 2 
and 3 currently seem realistic and for the latter option there are already therapeutic 
drugs, including valproate that have been approved for therapeutic interventions of 
other conditions.  
4.3. FUNCTIONAL CORRELATION OF BRD1 SCHIZOPHRENIA 
RISK ALLELES 
Genetic schizophrenia risk variants in and around the BRD1 gene have repeatedly 
been identified (Aberg et al. 2013; Nyegaard et al. 2010; Severinsen et al. 2006; 
Jorgensen et al. 2002). The schizophrenia associated SNPs in or near the BRD1 gene 
are part of a haploblock that spans both BRD1 and the nearby ZBED4 gene (Qvist et 
al., manuscript submitted). Cis-eQTL analysis using expression phenotypes of 
HapMap3 individuals revealed that the schizophrenia risk variants correlate with 
reduced BRD1 and not ZBED4 mRNA (Qvist et al., manuscript submitted). In study 
1, a metQTL analysis was performed using the MuTHER resource, a public 
available profiling dataset including Ilumina 450K adipose methylome data from 
648 twins (Grundberg et al. 2013). The 15 other SNPs in high linkage 
disequilibrium with rs138880 also revealed significant effects on the same probes 
that appeared affected by rs138880.  
 155 
   As described above, the rs138880 C-allele is predicted to harbour a binding site 
for the transcriptional repressor HES1 (Severinsen et al. 2006), whereas the A-allele 
may harbour binding sites for BPTF and RBP2. Thus, we believe that differences in 
transcription factor binding lead to increased methylation associated with the C-
allele and this is supported by the decreased transcriptional drive of promoter 
constructs carrying the rs138880 risk allele (Qvist et al., manuscript submitted). In 
Study 1 we find that rs138880 is associated with increased methylation at Region 2 
and 3 of the BRD1 promoter in blood, and these regions are important for regulating 
the minor transcript variants Exon 1C and 1B. This is in agreement with the limited 
approximate 3% reduction of BRD1 mRNA in carriers of the rs138880 risk allele in 
a B lymphoblastoid cell line established from HapMap3 individuals (Qvist et al, 
manuscript submitted). Collectively these observations strongly indicate that the 
rs138880 risk allele is the causative variant and that increased DNA methylation of 
the BRD1 promoter and reduced BRD1 expression on a well-founded basis can be 
considered an etiopathologic risk factor in schizophrenia. However, it should be 
noted that with the presumably limited decrease in expression of BRD1 in carriers of 
the rs138880 risk allele, and the high frequency of the risk allele (minor allele 
frequency of 0.16 in controls and 0.25 in schizophrenic individuals of European 
ancestry (Severinsen et al. 2006)), it is obvious that the risk allele is not alone 
sufficient to cause schizophrenia.  
 
4.4. FUNCTIONAL CONSEQUENCES OF BRD1 AND CHRNA7 
DEFICIENCY 
In the developing fetal pig brain BRD1 is highly expressed at early embryonic stages 
and its expression declines in the later stages (Severinsen et al. 2006). Interestingly, 
the two regions (Region 2 and 3) exhibiting increased DNA methylation in carriers 
of the rs138880 risk allele co-localise with CpG sites undergoing changes in DNA 
methylation levels during fetal brain development. Based on the increasing 
methylation at the Exon 1C promoter and concomitant decreasing methylation at the 
Exon 1B promoter it seems likely that expression of Exon 1C is higher in early fetal 
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brain development and gradually decreases whereas for Exon 1B it is the opposite. 
Importantly, the data also indicate that methylation changes in carriers of the 
rs138880 risk allele may adversely affect BRD1 expression in both the fetal and 
adult brain. But what is the functional consequence of reduced BRD1 expression? 
And is BRD1 a relevant target for treatment? The BRD1 gene is highly expressed in 
embryogenesis and inactivation of both alleles leads to impaired eye development, 
neural tube closure, and a lethal maturation defect in hematopoiesis (Mishima et al. 
2011). BRD1 regulates several genes acting in signalling pathways important during 
neurodevelopment (Fryland et al., manuscript submitted) and that helps explain the 
widespread deficits. Indeed, in Brd1+/- mice these genes are dysregulated and the 
mice display region-specific changes in dopamine levels and disturbed NMDA and 
GABA mediated signalling (Qvist et al., manuscript submitted). Overall the findings 
fit with the neurodevelopmental hypothesis of schizophrenia which suggest that 
disruption of brain development during early life followed by progressive 
neurobiological processes underlies emergence of psychosis (McGrath et al. 2003). 
BRD1 may however be equally important for the adult brain as it is regulated by 
both electroconvulsive seizures (Fryland et al. 2012) and chronic restraint stress in 
the hippocampus (Christensen et al. 2012). BRD1 is important for acetylation of 
histone H3K14 and binds in the promoter of several schizophrenia risk genes 
(Fryland et al., manuscript submitted). Combined with the knowledge that HDAC 
inhibitors exert hippocampal-dependent antidepressant like activities (Covington et 
al. 2011) this suggests that BRD1 may be involved in regulatory processes 
underlying stress adaptations (Christensen et al. 2012). Importantly, the stress 
induced BRD1 upregulation may be blocked or attenuated by increased DNA 
methylation of Region 2 and 3 in carriers of the rs138880 risk allele, which could 
prevent stress adaptions. This will depend on whether stress induced BRD1 
upregulation is mediated by transcription factors that are able to bind to methylated 
DNA as has been observed in some cases (Hsieh 2000) or if transcription factor 
binding is inhibited by methylation as has also been observed (Prendergast & Ziff 
1991; You et al. 2011). 
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    SNPs in the promoter region of CHRNA7 show significant association with 
schizophrenia (Stephens et al. 2009) and several rare promoter SNPs decrease 
promoter activity (Leonard et al. 2002). This corresponds well with observations of 
reduced α7 nAChR expression in hippocampus (Freedman et al. 1995) and cortex 
(Guan et al., 1999; Marutle et al., 2001) of schizophrenic individuals. Notably, the 
promoter SNPs are associated with failure to inhibit the P50 auditory evoked 
potential response, a deficit that is found in most schizophrenics and 50% of their 
first-degree relatives (Leonard et al. 2002). 
 
4.5. SMALL CHANGES IN METHYLATION LEVELS CAN IMPACT 
GENE EXPRESSION 
In study 1, 2, and 5 we examined changes in methylation and expression of target 
genes resulting from DNMT or HDAC inhibition. In study 1, focusing on BRD1, 
exposure of HeLa cells to zebularine decreased average methylation at Region 2 
from 92.2% to 68.7% whereas at Region 3 the average methylation decreased from 
15.2% to 10.5%. This was associated with upregulation of Exon 1C to 285% of 
control levels and upregulation of Exon 1B to 231% of control levels. In study 2, 
focusing on CHRNA7, HeLa cells were exposed to valproate and this resulted in a 
decrease in methylation at Region 1 from 19.9% to 18.8% and at Region 3 from 
22.6% to 20.3%. This was associated with 8.5-fold upregulation of CHRNA7. This 
emphasises that transcriptional activity depends on both epigenetic regulation and 
transcriptional drive. In general it seems like the methylation changes observed in 
psychiatric disorders are of modest size. For example in a recent study, by Pidsley et 
al. the 100 top-ranked schizophrenia associated differently methylated positions, 
revealed methylation levels 1-12% above or below control individuals with the 
majority showing differences around 5% (Pidsley et al. 2014). However, as 
described above although the methylation changes are rather small, the effects on 
transcription may be large.  
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4.6. IMPORTANCE OF LOW DEGREE METHYLATION 
In study 2, 3, and 5 we focused on regions that are methylated at very low levels. 
Low degree methylation has previously been reported to correlate with 
transcriptional repression of Arc and Gad1 in rats (Penner et al. 2011; Zhang et al. 
2010b). In study 2 we showed that methylation of Region 2+3 in the CHRNA7 
promoter in brain biopsies is very low with an average CpG methylation of 1.75% in 
the two biopsies with the highest methylation and an average of 0.65% for the 
reaming nine biopsies. Hence, there is approximately 3-fold difference in 
methylation levels with a corresponding 4-fold negative correlation in expression. 
Interestingly, the study clearly demonstrated the negative correlation between 
methylation levels at Region 2+3 and CHRNA7 expression. In study 3 and 5 we 
focused on methylation of the Arc promoter that is also methylated at a low degree. 
In study 5 we discuss how increasing HDAC activity could be involved in Arc 
repression and it has been established that HDAC2 and histone acetylation of H3 is 
also important for regulating Arc transcription (Moonat et al. 2013). However, we 
also find that DNMT inhibitor decitabine induces a significant upregulation of Arc 
expression, which suggests that even though methylation is low, the mechanism is 
essential for maintaining a transcriptionally inactive/low activity state. 
4.7. INTERACTION BETWEEN HISTONE ACETYLATION AND 
DNA METHYLATION 
In Study 2 we treated HeLa cells with valproate and this caused a decrease in 
methylation at Region 3 of the CHRNA7 promoter from 22.6% to 20.3%. This 
observation supports the interaction between histone modifications and DNA 
methylation. The process by which demethylation occurs could be similar to the 
process described in the introduction. Under normal circumstances the promoter is 
inactive and marked with repressive modifications e.g. H3K9me3 (Lin et al. 2007). 
Methylated DNA is recognised by methyl binding domain proteins (MBDs), such as 
MeCP2, that are part of large protein complexes containing HDACs and histone 
methyltransferases (HMTs) resulting in further transcriptional repression (Tsankova 
et al. 2007). Treatment of cells with HDAC inhibitor valproate would disrupt this 
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cascade by increasing histone acetylation, which could neutralise the positive charge 
of the lysine and destabilise internucleosomal contacts and lead to chromatin 
decondensation (Shogren-Knaak et al. 2006). As transcription from the promoter 
increases this could lead to active promoter demethylation involving TET enzymes 
as described in the introduction. 
   Although not included in study 2, methylation levels at Region 3 in HeLa cells 
treated with valproate was also examined by bisulfite sequencing. The analysis 
revealed the same tendency for decreased methylation as observed by 
pyrosequencing in the study. In addition, it revealed that even in this homogenous 
cell culture, the methylation patterns were very different in each cell, with the 
number of methylated CpG sites ranging from 1-6 out of the total 16 CpG sites in 
Region 3. Notably, treatment with valproate caused the percentage of clones being 
methylated at 0 or 1 CpG sites to increase from 17% in untreated cells to 37% after 
valproate treatment. This indicates that at least part of the increase in expression 
results from an increasing proportion of cells becoming transcriptionally active. 
 
4.8. PHARMACOLOGICAL PREVENTION OF SIDE EFFECTS 
INDUCED BY ECS 
ECT is one of the most effective treatments of major depression, but it is associated 
with both anterograde and retrograde memory impairments (Squire 1986; Lisanby et 
al. 2000). Anterograde memory impairments are particularly severe during the first 
few hours after ECT (Squire 1986; Sackeim et al. 2007; Smith et al. 2010) and 
capacity for learning usually takes up to 4 weeks to restore (Sackeim et al. 2007; 
Smith et al. 2010). In mice ECS causes rapid active DNA demethylation or de novo 
methylation at a high number of CpG sites in dentate granule neurons (Guo et al. 
2011b). These changes are accompanied by upregulation of de novo 
methyltransferase Dnmt3a and pre-infusion of DNMT inhibitor decitabine before 
ECS abolishes de novo methylation (Guo et al. 2011b). In study 5 we attempted to 
use the same strategy for preventing de novo methylation of the Arc promoter. It is 
known that regulation of Arc expression needs to be balanced as lack of Arc function 
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in knock-out mice leads to severe problems in memory consolidation (Plath et al. 
2006) whereas over-accumulation correlates with severe memory impairments 
(Greer et al. 2010). For rather obvious reasons the experiment was primarily thought 
as a proof-of-concept study. First of all learning and memory processes have been 
linked to rapid and dynamic regulation of DNA methylation (Miller & Sweatt 2007; 
Lubin et al. 2008; Penner et al. 2011). In addition, knockout of Dnmt1 and Dnmt3a 
results in abnormal long-term plasticity in the hippocampal CA1 region together 
with deficits in learning and memory (Feng et al. 2010a). Consequently, decitabine 
would undoubtedly by itself affect memory formation until being washed out. As 
discussed in study 5, an alternative strategy could be to inhibit HDAC activity. 
Indeed, it has been demonstrated that pre-treatment with the HDAC inhibitor 
phenylbutyric acid (PBA) reduced spatial memory deficits induced by ECS (Yao et 
al. 2010). It has been established that HDAC2 and histone acetylation of H3 are 
important for regulating Arc transcription (Moonat et al. 2013) but further studies 
are needed to reveal its potential in relation to ECS.  
4.9. HYDROXYMETHYLATION IS ABUNDANT IN THE 
MAMMALIAN BRAIN 
In recent years an additional DNA modification at the 5’ position of cytosine, 5-
hydroxymethylcytosine (5hmc) has attracted increasing attention (Wen & Tang 
2014). As described in section 1.1.1.1 in the introduction, 5hmc is an intermediate in 
the demethylation pathway, in a process involving oxidation of 5mc by TET 
enzymes. However, 5hmc is both abundant and stabile and evidence has emerged 
that 5hmc is also involved in regulating chromatin structure (Mellén et al. 2012). 
5hmc has been detected in all tissue and cell types investigated to date (Wen & Tang 
2014). Normal bisulfite conversion techniques do not distinguish 5hmc from 5mc 
and it has been estimated that 5hmc constitutes 10-20% of all methylated cytosines 
in mammalian brain tissues (Münzel et al. 2010). In a study mapping 5hmc and 
comparing the patterns to 5mc in the human brain it was found that 5hmc is more 
selectively targeted to genes than 5mc (Jin et al. 2011). Particularly, 5hmc is 
enriched at gene bodies and promoters and are largely absent from non-gene 
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regions. In promoters with high or intermediate CpG density 5hmc did not correlate 
with gene expression as opposed to presence of 5mc. However, in gene promoters 
with low CpG density there was a positive correlation between 5hmc and 
expression. In study 1, 2, 3, and 5 we used conventional bisulfite conversion and can 
therefore not distinguish 5hmc from 5mc. Studying 5hmc in all the settings could be 
informative, but particularly study 3 and 5, focusing on methylation of Arc could 
benefit from such studies. It has been found that neuronal activity decreases Tet1 
expression in CA1 of mice 3 hours after flurothyl-induced seizures (Kaas et al. 
2013). In the same setting it was found, that 24 hours post-seizures the total levels of 
both 5mc and 5hmc levels decreased significantly. This highlights that levels of 
5hmc are also affected by seizures. Furthermore, it was found that overexpression of 
TET1 induced increases in expression of several IEGs including Arc. However, it 
should be noted that expression of these genes was also significantly elevated in 
response to the catalytically inactive TET1m, suggesting that TET1 regulates the 
expression of these genes, at least partly, independent of 5mC to 5hmC conversion. 
Nevertheless, the abovementioned study highlights that 5hmc is highly relevant to 
study in relation to regulation of the Arc gene after ECS.  
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5. CONCLUDING REMARKS 
Over recent years an increasing amount of research have established that epigenetic 
mechanisms are importantly involved in etiology and treatment of psychiatric 
disorders. However, much work is needed to unravel the interplay between genetics, 
environment, and epigenetics. The studies included in this dissertation have 
provided important new knowledge regarding the epigenetic regulation of the genes 
BRD1 and CHRNA7. Regulation of BRD1 is particularly interesting in relation to 
neurodevelopment and mental disorders since BRD1 regulates several risk genes. 
Regulation of CHRNA7 on the other hand is particularly interesting as the gene is 
associated with the P50 deficit found in most schizophrenics, and as it encodes the 
α7 nAChR, which is considered a promising target for treatment of cognitive 
dysfunction. These genes are only two out of an abundant number of genes that have 
been associated with schizophrenia. The mechanisms associated with such genetic 
risk variants remain warranted. By studying gene expression of Dnmt3a and 
methylation and expression of Arc after ECS, we also tested the potential of using 
DNMT inhibition as a strategy to prevent ECS-induced side effects. Although the 
study did not reveal the desired effect, it revealed that decitabine attenuates ECS-
induced Dnmt3a upregulation and that Arc is most likely regulated by DNA 
methylation. In addition, the studies revealed that three different drugs, zebularine, 
decitabine, and valproate all affected DNA methylation in the applied settings. 
Future studies will shed light on the importance of epigenetic mechanisms in 
relation to psychiatric disorders and reveal the therapeutic potential of epigenetic 
modulation.  
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